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COMBINATORIAL ANALYSIS OF TUMORIGENIC MICRORNAS DRIVING 
PROSTATE CANCER  
 
 
By William T. Budd; PhD 
 
A dissertation submitted in partial fulfillment for the degree of Doctor of Philosophy at 
Virginia Commonwealth University.  
 
Virginia Commonwealth University, 2012 
 
Major Director: Zendra Zehner; PhD Biochemistry and Molecular Biology  
 
 
 
 Prostate cancer is the leading non-cutaneous malignancy affecting men in the 
United States. One in every six men will be affected by prostate cancer. Due to the high 
incidence of prostate cancer, there is a need to develop biomarkers capable of identifying 
tumors from benign prostatic lesions. miRNAs are small molecules that regulate protein 
translation and impact cellular integrity when dysregulated. It is widely thought that 
miRNAs have the potential to serve as biomarkers.  
 This study utilizes a unique combinatorial analysis of miRNA dysregulation to 
identify key miRNAs involved in prostate tumor initiation, progression and metastasis. 
Numerous dysregulated miRNAs potentially influence cancer development. A unique 
bioinformatically driven, network based approach was used to rank potential miRNAs 
that drive tumor progression. This study showed that miRNAs preferentially regulate 
highly connected proteins and transcription factors that affect numerous downstream 
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targets. Thus dysregulation of a single highly connected miRNA could severely impact 
homeostatic maintenance of the tissue.  
 In combination with miRNA profiling of a cancer cell progression model, the 
utilization of laser captured microdissection was used to separate cancer specific 
microRNA portraits from background differences arising from stroma cells, lymphocytes, 
and remaining normal epithelial cells. Integration of miRNA profiles with information 
gathered using networks biology and targeted proteomics resulted in the identification of 
a key miRNA that affects prostate cancer development and may be useful as a novel 
biomarker for identification/ staging of prostate cancer.  
 Human miR-125b was identified as a potential miRNA suppressor of tumor 
formation. Previous work has identified miR-125-b as the post-transcriptional regulator 
of the ErbB2/ ErbB3 growth factor receptor family. Loss of miR-125b drives up 
expression of ErbB2/ ErbB3 activating downstream PI3K/AKT and RAS oncogene 
pathways. The level of miR-125b decreases 3-5-fold between benign and tumor 
epithelium. Further, miR-125b decreases during the development of prostatic 
intraepithelial neoplasia, which is regarded as an early indicator of prostate cancer. Thus 
miR-125b may be an ideal marker of early changes indicative of cancer. Restoration of 
miR-125b into highly tumorigenic, metastatic cells reduces mobility and invasion of 
underlying tissues. Taken together these data show miR-125b is a tumor suppressor in the 
healthy prostate.  
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Chapter 1 
 
Introduction and Background 
  - 2 -
Background 
 
 Cancer is a highly heterogeneous, multifactorial disease that results from 
numerous genetic mutations, aberrant gene expression and miRNA dysregulation 1. 
Prostate cancer (CaP) is the most frequently diagnosed visceral carcinoma and the second 
leading cause of cancer related deaths of men in the United States 2. An estimated 
241,000 men will be diagnosed in 2012 3. It is predicted that nearly 27,000 will 
eventually succumb to the disease and likely that one of every six men will develop CaP 
during their lifetime. The death rate increases significantly as the tumor becomes more 
poorly differentiated and treatment options decline as the tumor leaves the confines of the 
prostate 4. Metastatic dissemination is the single most significant event occurring during 
prostate cancer progression. Despite the significance of metastasis, molecular events 
surrounding tumor progression and metastasis are poorly understood.  
 A variety of genetic and epigenetic factors such as age, race, heredity, diet, sexual 
frequency and physical activity are known to influence the development of prostate 
tumors 5. Important ethnic differences exist in prostate cancer epidemiology. Diagnostic 
rates vary dramatically across racial subgroups with the Hispanic male having the lowest 
rate of CaP diagnosis (Figure 1-1) 3. It is known that the diagnostic rate of prostate cancer 
in Hispanic men under estimates the actual number of Hispanic males with the disease as 
they are less likely than their Caucasian counterparts to participate in active screening by 
prostate specific antigen (PSA) analysis or digital rectal exam 6. Even though it appears 
the overall diagnostic incidence of prostate cancer is slightly lower in African-Americans, 
the age specific death rate is nearly two times higher. It is hypothesized that the death rate 
is higher in African-Americans because they are more likely to be diagnosed at a higher 
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clinical stage of tumorigenesis than their Caucasian counterparts 7.  The single greatest 
predictor of death from prostate cancer is the stage at diagnosis; the higher the stage at 
the time of diagnosis the greater the likelihood of death. It is imperative that the 
underlying causes of ethnic differentiation be determined and the disparity eliminated.  
 A recent study published in Cancer Causes and Control showed that lifestyle 
habits did not significantly differ between African-American and white men 8. The only 
potential variable that impacted prostate cancer diagnosis was education. The higher the 
education level of the patient, the more likely they were to participate in active screening 
methods and be diagnosed at an earlier stage. Men with graduate degrees have a lower 
death rate from prostate cancer than a man with a high school diploma or less (Figure 1-
2). Although the discrepancy is highest in African-American men, the trend applies to 
men of every race. The most likely reasons for the educational variation are an increased 
awareness of one’s health and better access to health care.  
 
Diagnosing prostate cancer 
 Evidence clearly demonstrates that early detection of prostate tumors reduces the 
likelihood of death from the disease 9. Although prostate cancer can only be definitively 
diagnosed by biopsy and histological examination, screening tools such as the prostate 
specific antigen (PSA) and digital rectal examination are useful in identifying patients 
that need biopsy. Prostate biopsy is not without risk. Bleeding and infection are 
commonly observed complications. The prostate biopsy is normally performed using a 
transrectal approach guided by ultrasound imaging. There is a large risk of infection as  
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Figure 1-1: Incidence and death varies among men of different ethnicities 
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Figure 1-1: Incidence and death varies among men of different ethnicities  
Analysis of data collected by the National Cancer Institute as part of the Surveilance, 
Epidemiology and End Results program 10. Data were separated into groups by race and a 
table generated using Microsoft Excel. 
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Figure 1-2: Death rate from prostate cancer decreases with higher education 
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Figure 1-2: Death rate from prostate cancer co-varies with race and education  
 
Analysis of data collected by the National Cancer Institute as part of the Surveillance, 
Epidemiology and End Results program 10. Data was separated into groups by race and 
table generated using Microsoft Excel.  
  - 6 -
 the needle passes from the rectum into the prostate. Many physicians minimize the 
incidence of infection through prophylactic antibiotic administration. The goal of active  
screening is to identify the population of patients that will receive the most benefit from 
biopsy.  
 Prior to the advent of the serum PSA test, it was estimated that only 25% of all 
prostate tumors were diagnosed and most were diagnosed at a later stage 9. A physician 
cannot diagnose prostate cancer using a PSA analysis in isolation. PSA testing is only 
useful as a potential indicator of disease 11. Studies show that in isolation the PSA is not a 
reliable indicator of disease and must be considered along with a digital rectal 
examination. The test is not as specific, many men have elevated PSA levels (>= 4.0 
ng/ml) without any indication of cancer. It is estimated that 75% of elevated PSA assays 
are not caused by cancer. There are many causes of PSA elevation including benign 
prostatic hypertrophy (BPH) and infection. 
  
Development of specific biomarkers to identify and stage prostate cancer 
 As PSA is not a specific indicator of prostate cancer, there exists a need to 
develop reliable biomarkers that can alert health care providers to the presence of early 
stage disease and distinguish indolent from aggressive tumors. Clearly, a great need 
exists for the development of more accurate biomarkers. In order to develop a more 
reliable marker for prostate cancer, one must understand the biological mechanism of 
tumor formation, progression and metastasis.  
 In recent years, microRNAs (miRNAs) have emerged as an important class of 
non-coding RNAs that influence post-transcriptional protein levels 12. In the presence of 
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external cues and environmental stressors, miRNAs have the ability to induce rapid 
changes in the proteome allowing the cell to respond in a more precise and energy 
efficient manner 1. Numerous cellular processes are affected by miRNA, including 
differentiation, growth/ hypertrophy, cell cycle control and apoptosis 13. Mature miRNAs 
are ~ 22 nucleotides in length and regulate protein levels by binding mostly to the 3’-
untranslated region (3’-UTR) of a messenger RNA, inducing translational repression or 
message cleavage. Aberrant expression of miRNAs contributes to the development of 
many pathological conditions including cancers of the breast, prostate, thyroid, and B-cell 
lymphomas 14. Even though miRNAs have been casually observed to be associated with 
cancer of the prostate, there is not a clear consensus on specific miRNAs that contribute 
to oncogenesis. Dysregulated miRNAs may be useful as potential biomarkers for prostate 
cancer, as it has been shown that miRNAs can be exported from the cell and are found in 
most biological fluids.  
 
Biogenesis of microRNA  
 The generation of miRNAs is a step wise process that results in the creation of a 
22 nucleotide segment of RNA that is capable of inducing mRNA cleavage or 
translational repression. miRNA genes can be found as a component of a polycistronic 
transcript consisting of two to seven miRNAs under the control of a common promoter, 
exist in intergenic regions of the genome, or be found in an intron under the control of 
that gene’s promoter 15, 16. Creation of the pri-miRNA begins in the nucleus under the 
control of RNA polymerase II and ends with a several hundred nucleotide RNA molecule 
that possesses a characteristic stem loop structure. The pri-miRNA has a 5’ cap and a 
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poly A tail on the 3’ end (Figure 1-3) 17. While in the nucleus, a ribonuclease like enzyme 
(Drosha) processes the pri-miRNA into a 70-100 nt fragment that retains the 
characteristic stem loop structure called a pre-miRNA. The pre-miRNA is exported into 
the cytoplasm by means of the nuclear export factor (Exportin V). Once in the cytoplasm, 
the loop of the pre-miRNA is cleaved and the stems are separated by Dicer into two 20-
25 nt strands (mature miRNA). One of the strands accumulates and is incorporated into 
the RNA induced silencing complex (RISC).  
 
miRNA function  
 Most eukaryotic genes are under the influence of at least one miRNA 18. Many 
genes are controlled by multiple miRNAs. Dysregulation of a single miRNA can affect a 
multitude of proteins and potentially lead to a cancerous phenotype. MiRNAs regulate 
target messages via several mechanisms. Perfect binding between a miRNA and the 
target sequence will typically result in direct cleavage of the phosphodiester bond 
between nucleotides 10 and 11 of the target mRNA 19. Message cleavage is carried out 
only by RISC complexes that contain Ago2 20. Incomplete complementarity of the 
miRNA to the 3’-UTR of the message is traditionally thought to result in translational 
inhibition 18. Most mRNA degradation occurs through deadenylation, decapping and 5’-
3’ exonuclease degradation. Proteins needed for mRNA degradation have been shown to 
concentrate in cytoplasmic processing bodies (PBs). Experiments have shown that 
miRNAs and mRNA gene reporters also accumulate in these PBs, suggesting that co-
localization of the miRNA/ mRNA may be another method of translational repression/ 
degradation.  
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Figure 1-3: Biogenesis of microRNA 
 
 
 
Figure 1-3: Biogenesis of miRNA 
1. RNA polymerase II transcribes a 200- 700 nucleotide segment that is 
polyadenylated and 5’ capped (pri-miRNA) 
2. Ribonuclease enzyme (Drosha) processes the pri-miRNA into a 70-100 nt 
fragment known as the pre-miRNA  
3. The pre-miRNA possesses a characteristic stem loop structure  
4. Exportin V exports the pre-miRNA into the cytoplasm 
5. The Dicer complex recognizes the characteristic stem loop structure and cleaves 
the pre-miRNA into a smaller RNA of approximately 22 nt (mature miRNA) 
6. Each pre-cursor has the potential to generate two mature miRNA molecules 
7. The mature miRNA recognizes complementary bases of the messenger RNA. The 
greatest numbers of proven interactions have been identified in the 3’ UTR of 
message.  However, interactions have been observed in the 5’ UTR and within the 
coding sequence.  
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 Many miRNA genes are dysregulated in cancer and influence tumor formation/ 
progression because they are located in regions of the genome that are commonly 
overexpressed or deleted 21. Dysregulated miRNAs have been shown to contribute to 
oncogenesis by the loss of tumor suppressing miRNAs or increased expression of 
oncomiRs 22. While tumor suppressing miRNAs are lost or reduced during oncogenesis, 
oncomiRs are amplified or overexpressed. Either loss of tumor suppressors or increased 
expression of oncomiRs ultimately results in increased cell growth, proliferation, 
invasiveness or metastasis.  Aberrant expression of even a single miRNA has the 
potential to influence a large number of cellular processes as it is predicted that each 
miRNA has the potential to affect hundreds of proteins. Thus, dysregulation can 
destabilize homeostatic balance by affecting levels of a multitude of target proteins.  
 
Genetically related prostate cancer progression model  
 Through the utilization of a unique genetically related prostate cancer cell 
progression model, we are able to identify miRNAs that likely contribute to prostate 
cancer initiation, progression and metastasis. Cell lines were derived through the 
immortalization of non-neoplastic prostate epithelium with SV40 large T antigen under 
the control of a SV40 promoter 23. The parental (P69) cell line is poorly tumorigenic, and 
non-metastatic. P69 cells have a lower modal chromosome number than most other 
prostate cancer cell lines in use as these have been typically isolated from metastatic sites 
(LnCap, DU145, and PC3).  An in vivo selection process was used to create cells with  
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Figure 1-4: Development of genetically related prostate cancer cell lines 
 
Model for the development of a unique, genetically- related cancer progression model is 
presented. Human prostate epithelial cells immortalized with SV40 large T antigen were 
injected into a mouse and expanded using an in vivo selection process. At each passage, 
the cells acquired increased tumorigenic propensity as shown. The M12 subline possesses 
highly tumorigenic behavior and metastatic potential with 100% of mice injected 
suffering from disseminated cancerous lesions.  
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Figure 1-4: Development of genetically related prostate cancer cell lines 
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increased tumorigenicity and metastatic potential.  After several rounds of in vivo 
selection following intra-prostatic and intra-peritoneal injections, a highly tumorigenic 
and metastatic variant (M12) was isolated. M12 cells routinely metastasize in nude, 
athymic mice following intra-prostatic/ intra-peritoneal injection and contain a 
chromosome 16:19 translocation. Restoration of chromosome 19 in M12 cells resulted in 
a variant that was less tumorigenic and non-metastatic (F6) 24. These prostate cancer cell 
lines are unique as they are not derived from a primary tumor and are genetically related. 
They provide a model to study the molecular events that occur during prostate 
tumorigenesis and metastasis. 
 
Identification of dysregulated miRNAs in prostate cancer cell progression model 
 Microarray technology has allowed researchers to simultaneously profile 
hundreds to thousands of molecules in a single assay 25. The advent of array based 
profiling of miRNA expression is difficult because of the nature of the molecule 26. 
miRNAs are on average only 22 nucleotides in length, vary dramatically in their 
abundance and melting temperature, and often only differ from one another by a single 
base. Despite the challenges, several technologies have been used with a modest degree 
of success 25. Radiolabeled northern blots, bead based profiling methods, oligonucleotide 
arrays, and quantitative real time PCR applications have been utilized. Until recently, all 
of the methods described have been limited to samples for which one can obtain a 
relatively large amount of starting material.  
 The advent of locked nucleic acid technology has increased the sensitivity and 
specificity of miRNA based arrays 26, 27. Locked nucleic acids have a reduced 
  - 14 -
conformational flexibility through the incorporation of a methylene bridge between the 
4’- carbon atom and 2’- oxygen of the ribose ring 28.  Interspersion of locked nucleic acid 
nucleotides among non-locked nucleotides allows for fine tuning of the melting 
temperature of oligonucleotides. The inclusion of a single LNA base increases the 
melting temperature 2-10°C. LNA modified probes can be optimized in such a manner 
that a uniform melting temperature and normalized hybridization conditions can be 
established. LNA modified probes are ideal for profiling the entire miRnome as they have 
higher sensitivity and higher specificity than standard oligonucleotide probes. This 
technology allows researchers to profile precious tissue with a lower amount of starting 
RNA.  
 Several studies have reported numerous differences in miRNA expression that 
arise during cancer progression 25, 29, 30. It remains to be determined for most of the 
miRNAs shown to be dysregulated, whether their aberrant expression is a cause or a 
consequence of cancer 31. Evidence shows that aberrant expression of a single miRNA 
can induce oncogenic transformation 32. Transgenic mice that overexpress miR-155 
suffer a condition that mimics lymphoblastic leukemia. Although miR-155 has been 
shown to be causative in acute lymphoblastic leukemia, evidence for a potential role in 
prostate cancer is unclear.  
 Human-miR-21 has been described as the ubiquitous solid tumor oncomiR and is 
overexpressed in prostate, lung, pancreas, breast, stomach, and colon cancers 33. Despite 
claims that increased miR-21 expression is observed in prostate cancer, it has been shown 
that knockdown of miR-21 does not affect proliferative or invasive properties in DU145 
and PC3 cancer cell lines 34. In matched human samples, there are approximately as many 
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men with prostate cancer that have increased miR-21 expression as those that do not. A 
role for miR-21 in the progression of CaP is not clear.  
 Attempts to identify a miRNA signature of prostate cancer using screens have 
failed to reveal a consistent pattern that can identify malignant epithelium from its normal 
counter part. The results are inconclusive and often contradictory. There are several 
potential reasons for disagreement among profiles. Improper study design, 
underestimated treatment of patients, underlying heterogeneity of the tissue, and platform 
inconsistencies are just a few of the reasons for potential disagreement among studies 35.  
 
Identification of key signaling proteins affecting tumorigenesis 
 The advent of high throughput technologies has enabled researchers to identify 
hundreds of genetic mutations that lead to oncogene activation 36. Previous researchers 
have shown that point mutations do not occur randomly in known oncogenes. Instead, 
there exist a relatively small number of codons that are affected disproportionately. There 
are many methods that can be utilized to discover somatic mutations that may be driving 
cancer progression. These mutations are often described as oncogenic “hits”. Oncogenic 
mutations confer a survival advantage to the cell by aberrant influence of intracellular 
protein signaling pathways 37.  
 Common pathways that influence cancer progression are survival, growth, 
apoptosis, and cell cycle control pathways. Genetic sequencing and gene expression 
profiling cannot determine pathway activation. It has been shown that mRNA levels 
correlate poorly with the amount of an active protein. In order to determine the activation 
level of signaling proteins, proteomic technology is needed. Reverse phase protein 
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microarrays (RPMA) allow for the simultaneous evaluation of hundreds of proteins at a 
single time point 37. 
  RPMA was developed to interrogate a small number of cells and measure 
multiple analytes 37, 38. RPMA arrays immobilize a protein analyte onto an array substrate 
and probe with an antibody. Potentially, hundreds of samples can be adhered to a single 
array. As only minute amounts are spotted onto the array, a sample can be extended 
across hundreds of slides. This approach allows researchers to profile hundreds of 
proteins across hundreds of samples and better characterize the intracellular signaling 
proteome.  
 
Confirmation of microRNA dysregulation in human samples 
 Many studies have used human tissue obtained from prostatectomy or biopsy in 
an attempt to identify potential miRNA markers of cancer progression. For the most part, 
these studies have failed to identify miRNAs that can be used as biological markers for 
the diagnosis of prostate cancer let alone can be utilized to stage prostate tumors 39. 
Nearly all of the published work using miRNA screens of human prostate tumors utilizes 
homogenized tissue following gross dissection. It is likely that the tissue being analyzed 
remains contaminated with other cell types such as stroma, blood vessel, nerves, smooth 
muscle or lymphocytes. In order to accurately profile a tissue’s disease state, diseased 
cells must be removed from surrounding tissue and examined in a pure cell population 40.   
 Laser capture microdissection (LCM) is a technique that allows one to isolate 
pure cell populations from heterogeneous tissues 40. LCM uses infrared and/or ultraviolet 
lasers to attach visualized cells to a thermolabile polymer cap. Not only can pure 
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populations of normal epithelium and stroma be separated from diseased tumor 
epithelium or activated stroma, but ultimately tumor cells at varying stages of disease can 
be individually captured. After dissection, the captured cells can be used to analyze all 
types of biological macromolecules, such as miRNAs, mRNA, or proteins can be isolated 
from these pure populations of captured cells.  
 
Systems biological perspective 
 It is essential to have an understanding of the individual molecules that contribute 
to complex phenotypes such as cancer and metastasis 41. However, complex systems are 
not just an assembly of genes, proteins, and other macromolecules. Emergent properties 
arise out of complex non-linear interactions amongst all the molecules in a cell. 
Traditional molecular biological and biochemical studies have uncovered many 
molecules that contribute tumorigenic properties upon dysregulation. Traditional 
reductionist approaches have viewed the human body as a collection of constituent parts 
42. The tradition of medicine has been to isolate and treat the defective component in 
isolation and hope the result is indicative of the whole. Unfortunately, complex 
phenotypes cannot be reduced to a single molecule as they discount the emergent 
properties that arise from the non-linear interaction of multiple components. The 
reductionist approach has been quite successful at treating many conditions but has failed 
to eradicate more complicated pathologies such as cancer. Cancer is the end result of 
numerous alterations in biochemical pathways and networks 43.  
An alternative to the traditional reductionist philosophy is the concept of systems 
biology. Systems biologists seek to gather information about multiple types of molecules 
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(genes, proteins, RNA) in the cell and integrate the information in order to understand the 
perturbations underlying a given pathology from a systems level. High throughput 
technologies such as DNA microarray, genome sequencing, proteomics, and qRT-PCR 
profiling allow for the simultaneous acquisition of thousands data points. Integration of 
multiple data sources increases the likelihood of identifying key pathways involved in 
cancer initiation, progression and metastasis.   
Complex interactions can be modeled as a biological network with the 
macromolecule represented as a node and interactions modeled as edges 1. Network 
properties are described mathematically. An important indicator of molecular importance 
is node degree. A highly connected node is more likely to be essential and cause disease 
when dysregulated 44, 45.  
 
Network properties identify key proteins affected by miRNA dysregulation 
 Traditionally, researchers using array based methods rank significance based on 
relative expression differences. This method assumes that the most differentially 
expressed miRNA is the most significant contributor to the observed phenotype. It is 
reasonable to hypothesize that small changes in some miRNAs may effect large changes 
in the tissue as some targets are more important than others. It is well known that highly 
connected proteins are more likely to be essential, and disease associated 44, 45. 
Perturbations of these highly connected proteins are more likely to result in diseases such 
as cancer 1.  
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Hypothesis  
 This project utilizes a unique combinatorial approach to understand the impact of 
miRNA dysregulation upon prostate cancer progression. A novel isogenic prostate cancer 
cell progression model has been selected as it more closely mimics tumor progression as 
it occurs in vivo. I propose that miRNA profiling of these unique cell lines will better 
serve to identify miRNAs that contribute to cancer progression and metastasis. Arrays 
that utilize LNA™ modified probes are more advantageous than other array technologies 
currently in use as they are more sensitive and more specific. Differences in miRNA 
expression will be verified using quantitative real time PCR (qRT-PCR) with either 
TaqMan® probes or Exiqon® LNA™ probes.  
 miRNA significance will be ranked not just by expression differences but rather 
the identification of critical downstream protein nodes through the use of methods used in 
biological network analysis. As miRNAs affect protein levels, key signaling molecules 
will be measured using the RPMA format in conjunction with the George Mason 
University Center for Applied Proteomics and Molecular Medicine. Integration of 
miRNA profiles and proteomic data have the potential to increase the success of 
identifying novel miRNAs affecting tumorigenesis in the cancer progression model. It is 
our hypothesis that a combinatorial analysis of an RPMA profile and a miRNA array will 
reveal dysregulated miRNAs that affect significant downstream targets imparting an 
onocgenic advantage. The combination of the data revealed in the cancer cell line 
miRNA screens, RPMA proteomics along with information from our networks analysis 
will be used to rank the dysregulated miRNAs and each will be verified in human 
samples. We propose that the utilization of laser capture microdissection to obtain a pure 
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cell population from a heterogeneous prostate tumor sample will reveal miRNAs that can 
be used for diagnostic purposes. Overall, this combinatorial approach will reveal 
miRNAs that drive prostate cancer progression when dysregulated and may be useful as 
newer, more relevant biomarkers to identify and stage prostate cancer.  
 
Specific aims of project  
• Identify key microRNAs involved in prostate tumorigenesis using a systems 
biological approach.  
• Using an Exiqon® miRNA screening platform with RNA collected from 
genetically related prostate cancer cell lines. Develop a list of prioritized miRNAs 
that affect key proteins involved in tumorigenesis of the prostate gland. . 
• Measure the relative expression levels of the priority miRNAs determined in aim1 
using microdissected tissue of malignant cells and benign cells obtained from 
flash frozen human prostate biopsy samples.  
• Modify the expression of the differentially regulated miRNAs in a prostate cancer 
cell model and evaluate effects on tumorigenesis using a variety of in vitro 
analyses.  
• Ultimately the effect of miRNA modulation on tumorigenic and metastatic 
properties will be evaluated in male, nude, athymic mice (Future Studies). 
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Chapter 2 
Networks analysis reveals preferential miRNA regulation of highly connected 
protein nodes 
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Complex physiological processes can rarely be ascribed to a single molecule 46. 
Instead, they arise out of the interaction and coordination of large numbers of proteins, 
nucleic acids, and other macromolecules. Healthy organisms intricately regulate 
thousands of components with remarkable fidelity and accuracy 1. Protein-protein 
interactions are essential to many biological processes and mediate many of the reactions 
necessary to sustain life. A key strategy to understand the molecular workings of the cell 
is the systematic identification of crucial protein interactions 47. 
 These interactions can be modeled as a biological network with proteins 
represented as nodes and interactions among the proteins represented as edges. 
Topological features of the network can be described mathematically and used to infer 
molecular contribution to network/cellular stability. As observed, widespread miRNA 
dysregulation contributes to the development of many forms of cancer including cancer 
of the prostate. This work utilized a systems based, network approach to understand the 
impact of miRNA dysregulation on the overall stability of a protein-protein interaction 
network (Figure 2-1). 
 
Identification of dysregulated miRNAs contributing to prostate cancer 
 
 MiRNAs associated with prostate cancer (111) were compiled from the 
miR2disease online resource 48. Utilizing the built in search function for miRNAs 
associated with a specific disease, the database was queried using the term “prostate 
carcinoma”  to identify miRNAs related to prostate tumorigenesis and included both 
causal and unspecified relationships. Using a PERL script, each miRNA was further 
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evaluated to extract information regarding its expression pattern and literature references 
for each dysregulated miRNA.  
 
Proven targets of miRNAs associated with prostate cancer 
 A comprehensive record of proven miRNA/gene interactions was assembled from 
the Tarbase and miRecords repositories of experimentally supported miRNA targets 
downloaded in May 2011 49, 50. Utilizing a PERL script, multiple entries were eliminated 
and both resources were combined into a single non-redundant list. Dysregulated 
miRNAs contributing to prostate cancer were associated with validated targets using our 
comprehensive record.  
Prostate gland transcriptome profiles were obtained from the Unigene database in 
order to build a protein-protein interaction network of prostate specific miRNA/ target 
interactions 51. Transcripts that show any level of expression in the prostate gland were 
extracted and identifiers converted to HUGO gene symbols using a PERL script. By 
combining the information obtained from the miR2disease database, comprehensive 
miRNA/ target interactions and the list of expressed transcripts in the prostate, we 
compiled a total of 608 confirmed protein targets that are affected by miRNA 
dysregulation in the prostate.  
 
Literature mined prostate protein-protein interaction network 
The Agilent literature search (v2.76) tool was used in conjunction with Cytoscape 
2.8 to infer two protein-protein interaction networks 52, 53. The first was built using known 
prostate cancer miRNA targets. Each protein in the candidate list of 608 known prostate 
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cancer miRNA target proteins was used as a search term in the Agilent literature search 
tool and the search was controlled to limited interactions to Homo sapiens with a 
maximum of 10 hits per search string/ search engine. The second network was built in the 
same manner using 608 randomly chosen proteins that are expressed in the prostate gland 
according to the Unigene database but chosen without regard to known miRNA status 51. 
Following network inference, visualization was accomplished using Cytoscape and 
topological network descriptors were estimated using CentiScaPe 54.  
 
Randomization of prostate miRNA target protein-protein interaction network 
The prostate cancer miRNA target network was shuffled 50,000 times using a 
degree preserving edge shuffle random network plugin developed by engineers at 
Syracuse University and implemented in Cytoscape. The plugin was downloaded 
(http://sites.google.com/site/randomnetworkplugin/Home) as a .jar file and installed in 
the Cytoscape package. The application was run across two processors and repeated 
50,000 times to generate the best results.  
 
Transcription factor analysis 
 Transcription factors were compiled from the TFCAT curated catalog of 
transcription factors 55. Only genes determined to be transcription factors were 
downloaded and the default choice was selected for the remaining download filtering 
options. The file was exported into a tab delimited text file and a PERL script utilized to 
remove any redundant proteins. After filtering, there were a total of 3419 transcription 
factors.  
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 Transcription factors targeted by miRNAs dysregulated during tumorigenesis of 
the prostate were compiled by intersecting the list of miRNA targets with the table of 
transcription factors using PERL. The process was repeated using the list of randomly 
associated proteins.  
 
Statistical analysis  
 Differences in network distributions were evaluated using an Analysis of 
Variance test (ANOVA) with significance set at probability <= 0.05. All statistical 
analyses were performed using JMP 8.0 (Statistical Analysis Software Cary, NC). The 
distribution of node degree for the prostate miRNA targeted network and the randomly 
selected prostate protein network were created using the R Project for Statistical 
Computing (http://www.r-project.org/).  
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Figure 2-1: Outline of process to determine network properties of miRNA targets 
MiRNAs contributing to the development of prostate carcinoma were downloaded from 
miR2Disease and associated with proven targets. A protein-protein interaction network 
was inferred using literature references with Agilent Literature Search. Network 
properties were calculated using CentiScape and pathway enrichment was estimated 
using Agilent.  
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Figure 2-1: Outline of process to determine network properties of miRNA targets 
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Analysis of miRNA contributions to prostate tumorigenesis 
Dysregulation of miRNAs may result in tumor formation and progression through 
the increased expression of oncomiRs or decreased expression of tumor suppressors.  
Mir2disease is a manually curated database which associates experimentally supported 
miRNA dysregulation with disease 48. Consideration of only experimentally proven 
miRNA/ disease associations will not reveal every miRNA that is involved in prostate 
cancer. However, this approach is more favorable than approaches that consider putative 
interactions as they suffer from an inherent lack of sensitivity evidenced by large 
numbers of false positive predictions.  A search of the miR2disease database reveal a 
total of 111 miRNAs that contribute to prostate tumorigenesis and cancer progression 
when significantly dysregulated. It remains to be determined whether or not miRNA 
dysregulation is the cause of tumorigenesis, a consequence of tumorigenesis or both. 
Previous authors had observed a global decrease of miRNA expression levels during 
tumorigenesis leading to the hypothesis that most miRNAs function as tumor suppressors 
56. Our analysis using the miR2diease database finds that there are approximately as 
many oncomiRs as tumor suppressing miRNAs. Sixty microRNAs showed increased 
expression levels (oncomiRs) in tumor samples compared to normal tissue whereas 51 
miRNAs decreased in tumor samples (tumor suppressors) (Figure 2-2).   
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Figure 2-2: microRNA dysregulation in prostate cancer 
 
 
 
 
 
 
 
Figure 2-2: microRNA dysregulation in prostate cancer 
microRNAs dysregulated during prostate cancer progression were extracted from the 
miR2disease database along with their potential role in cancer development as defined by 
their expression profiles 48. A Venn diagram illustrating the numbers of oncomiRs, tumor 
suppressors, and miRNAs that can function as either oncomiRs or tumor suppressors was 
created.  
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 Interestingly, there are 11 examples in which the same miRNA displays 
contrasting behaviors in prostate tumors. These have the potential to act as either 
oncomiRs or tumor suppressors during tumorigenesis. Their expression level may vary 
depending upon the degree of cellular de-differentiation. For example hsa-miR-125b 
(miR-125b) has been reported by several groups to significantly decrease during 
tumorigenesis. MiR-125b coordinately regulates two members of the human epidermal 
growth factor receptor family (ErbB2/HER2/ NEU, ErbBB3/HER3) 14, 25, 57, 58. Decreased 
expression or loss of miR-125b results in an increase in both ERBB2/ERBB3 protein 
levels thereby enhancing the invasive potential of the cell leading to tumor formation and 
progression 59.  
Conversely, the androgen independent LNCaP sublines (CDS1 and CDS2) 
produce higher levels of miR-125b compared to the androgen dependent LnCaP sublines 
58. Treatment of androgen dependent LNCaP cells with synthetic miR-125b allowed them 
to survive in androgen depleted media. The cellular effects of miR-125b under androgen 
dependent conditions are mediated through the translational suppression of BAK1 14. 
BAK1, a member of the BCL2 protein family, functions as a pro-apoptotic factor 60. 
Suppression of pro-apoptotic factors increases the oncogenic potential of the cell.  
A similar finding is observed with hsa-miR-146a, which can function as an 
oncomiR in many tumors, but in androgen independent tumors functions as a tumor 
suppressor 25, 61.  Altogether these two examples illustrate how a single miRNA (miR-
125b, miR-146a) can function as a tumor suppressor or an oncomiR dependent upon 
another variable, in these cases androgen dependence. Most likely similar situations 
could be found for the other overlapping group members.   
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Protein-protein interaction of prostate cancer miRNA targets show scale free 
behavior 
Nearly every biological process depends upon protein-protein interactions 62. 
Disruptions or perturbations in these interactions underlie many human diseases 
including cancer. Protein- protein interactions are modeled using a system based, network 
approach and described mathematically. Two protein- protein interaction networks were 
built with information gathered from the PubMed , Online Mendelian Inheritance in Men, 
and the US Patent Office databases using the Agilent Literature Search plugin in 
Cytoscape. Topological network characteristics were measured using CentiScaPe 52, 54, 63.  
The first network was built using proven targets of dysregulated miRNAs shown 
to contribute to the development of prostate cancer. A second similar network of 
randomly sampled proteins expressed in the prostate, but chosen without regard to 
miRNA status was compiled. Both the network of dysregulated miRNA protein targets 
and randomly selected prostate proteins possessed a scale free form (Figure 2-3). 
However, they differed in the average connectivity as measured by node degree with the 
miRNA targeted network having a much higher average connectivity measure. Node 
degree is a measure of interactions among the molecules in a network. In a scale free 
network, as the node degree increases, the frequency observed decreases, with most 
nodes having only a few connected neighbors. This functional organization commonly 
seen in a complex system ensures redundancy in the system resulting in some amount of 
fault tolerance 46. 
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Figure 2-3: Targets of miRNAs are more highly connected than randomly chosen 
proteins 
 
 
Two shortest path protein-protein interaction networks were built using the Agilent 
literature search function within Cytoscape 2.8 and topological measures evaluated using 
CenstiScaPe 2.76. The first network was built using proven targets of miRNAs that are 
dysregulated during the development of prostate cancer (Red). The other network was 
built from randomly chosen proteins that are expressed in the prostate but chosen without 
regard to miRNA status (Blue). Frequency distributions of the node degree for the two 
shortest path networks are displayed 
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Figure 2-3: Targets of miRNAs are more highly connected than randomly chosen 
proteins 
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MiRNAs dysregulated in prostate cancer preferentially regulate highly connected 
proteins 
Node degree is one topological measure that can be used to infer the contribution 
of a protein towards cellular/network stability. Analysis of the average node degree 
revealed an overall enrichment of highly connected proteins in the prostate cancer 
miRNA target network not seen in the network of randomly selected prostate proteins 
(p<= 0.0001) (Table 2-1). The average protein in the miRNA targeted network was 
connected to nearly 30 other proteins. Conversely, the average protein in the randomly 
chosen network was only connected to approximately 5 others. Of the top candidates in 
the prostate cancer miRNA targeted network, mitogen-activated protein kinase 14 
(MAPK14) was the most connected with a node degree of 290. It is important to note that 
the node degree represents a maximum protein potential, not all 290 proteins will interact 
with MAPK14 at the same time. Instead, MAPK14 will interact with a small number of 
proteins at any one moment and the neighbors change depending upon the needs of the 
cell. The most highly connected protein in our randomly generated prostate network was 
only connected to 28 other proteins, a ten-fold difference. A list of prostate cancer 
miRNA targeted proteins with a node degree over 200 is included in Table 2-2. This list 
is rich in well known cancer related proteins, many of which are current or proposed drug 
targets.  
Perturbation of these highly connected nodes is more likely to negatively impact 
network stability 1.  It has been shown that molecules with a higher node degree are 
essential to the cell and their loss often results in a disease state such as cancer 44, 45. 
There is a positive correlation between protein essentiality and connectivity indicating  
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Table 2-1: Comparison of network node distribution of the prostate cancer miRNA 
target network and the randomly chosen prostate protein network 
 
Network Mean 
Degree 
Standard 
Deviation 
Minimum Maximum  
Prostate cancer miRNA 
target protein  
29.80 47.75 1 290 
Random prostate protein 4.46 4.24 1 28 
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Table 2-2: Protein nodes with connectivity degrees greater than 200 
Protein Name 
Node 
degree Function Known miRNA 
MAPK14 Mitogen activated 
protein kinase 14 
290 Cell proliferation, 
differentiation, and 
transcription regulation 
hsa-miR-124, hsa-miR-24 
SP1 SP1 Transcription 
Factor 
269 Cell growth,  differentiation, 
and apoptosis 
hsa-miR-218, hsa-miR-124, hsa-miR-29b 
VEGFA Vascular endothelial 
growth factor 
267 Angiogenesis, 
vasculogenesis, and vascular 
endothelial cell growth 
hsa-miR-205, has-miR-200b, hsa-miR-126, 
hsa-miR-93  
CASP3 Caspase 3 258 Execution phase of apoptosis hsa-let-7a,  hsa-let-7e 
MYC Transcription factor 254 Cell cycle progression, 
apoptosis, and cell 
transformation 
hsa-miR-24, hsa-miR-145, hsa-miR-34c-5p,  
hsa-miR-34a, hsa-miR-34b*, hsa-let-7c 
EGFR Epidermal growth 
factor receptor 
248 Cell proliferation hsa-miR-1, hsa-miR-7,  
hsa-miR-16 
BCL2 B-cell lymphoma 2 247 Apoptosis hsa-miR-15, hsa-miR-1, hsa-miR-20a, hsa-
miR-34a, hsa-miR-181a, hsa-miR-296-5p, hsa-
miR-15a, hsa-miR-153, hsa-miR-17, hsa-miR-
15b  
CTNNB1 Catenin Beta 1 232 Cell growth regulator and cell 
adhesion 
hsa-miR-155 
JUN Jun proto oncogene 229 Transcription factor, 
angiogenesis, apoptosis 
hsa-miR-15a, hsa-miR-16, hsa-miR-30 
TNF Tumor necrosis factor 217 Cell proliferation, 
differentiation, apoptosis, lipid 
metabolism, and coagulation 
hsa-miR-146a 
FGF2 Fibroblast growth 
factor 2 
216 Cell proliferation, 
angiogenesis 
hsa-miR-16 
TP53 Tumor protein 53 213 Cell cycle regulation and 
apoptosis 
hsa-miR-129-5p, hsa-miR-125a-5p, hsa-miR-
1285, hsa-miR-125b  
PPARG Peroxisome 
proliferator activated 
receptor gamma 
213 Regulator of adipocyte 
differentiation 
hsa-miR-27b 
ESR1 Estrogen receptor 1 212 Cell growth, differentiation, 
and sexual reproduction 
hsa-miR-302c,  hsa-miR-20b, hsa-miR-19b, 
hsa-miR-18a, hsa-miR-181a, hsa-miR-206, 
hsa-miR-22, hsa-miR-181b, hsa-miR-193b, 
hsa-miR-19a 
TGFB1 Transforming growth 
factor beta 1 
208 Cell proliferation, 
differentiation, adhesion, and 
migration 
hsa-miR-141, has-miR-128a 
CCND1 Cyclin D1 203 Cell cycle control  hsa-miR-16, hsa-let-7b, hsa-miR-17, hsa-miR-
195, hsa-miR-34a, hsa-miR-20a, hsa-miR-15a, 
hsa-miR-19a, hsa-miR-155, hsa-miR-503 
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that the more connected a protein is, the greater the likelihood that it is essential to life. 
Conversely, molecules with a lower number of connecting neighbors are not as likely to 
disrupt the system when they are perturbed. Disease causing genes are more likely to 
encode highly connected proteins 64, 65. This analysis indicated that miRNAs have a 
strong likelihood of impacting the network structure and dysregulation is more likely to 
affect essential proteins causing diseases like cancer.  
 Randomization of the prostate cancer miRNA targeted network was performed to 
estimate the likelihood that this arrangement arose out of chance.  The network was 
compared to a null model made by a shuffled (50,000 X) version of itself 66. Shuffling 
was accomplished using an algorithm that preserves the overall node degree distribution 
in order to emulate the properties found in the prostate miRNA targeted network. The 
randomized networks did not result in a mean clustering coefficient (C = 0.029) similar to 
the protein-protein interaction network (C = 0.621).  This measure is evidence that the 
arrangement of the proteins in this network is not random, but results from clusters of 
associated proteins, as would be expected in a complex, living system.  Randomly 
generated networks of the same degree and distribution do not maintain this modularity.   
 
OncomiRs regulate more highly connected proteins than tumor suppressors 
A one way analysis of variance (ANOVA) revealed statistically significant 
connectivity differences among the targets of oncomiRs and targets of tumor suppressing 
miRNAs (F2, 503 = 6.2821,  p=0.002). Oncogenic miRNAs showed a regulatory preference 
towards more highly connected proteins. While the connectivity of an oncomiR target 
was 39, the average connectivity of a tumor suppressor miRNA target was only 27 other 
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proteins (Table 2-3). Interestingly, the targets of the 11 miRNAs that can function as 
tumor suppressors or oncomiRs depending upon a second variable exhibited a much 
higher average target node degree (61) than either oncomiRs or tumor suppressors alone.  
Cancer related proteins in general show greater node degree and higher 
connectivity than non-cancer associated proteins 67, 68.  The protein products of tumor 
suppressing genes are known to be more centrally located and more highly connected 
than the products of oncogenes 69. In our analysis we found that the connectivity of 
oncomiR targets was higher than the targets of tumor suppressing miRNAs. It is 
important to remember that miRNAs are negative regulators of protein translation and the 
targets of oncomiRs would be tumor suppressive proteins. This analysis confirmed that 
miRNA dysregulation contributed to the development of prostate cancer.   
 
Highly connected proteins possess more than one miRNA binding site 
A comparison of proteins in the prostate cancer miRNA targeted network 
revealed that there was a positive correlation between protein connectivity and the 
number of different experimentally proven miRNA binding sites in the 3’-UTR (Figure 
2-4). That is, as a protein interacts with a higher number of other proteins, it is more 
likely to be regulated by multiple miRNAs. MiRNAs may act cooperatively through the 
simultaneous interaction of multiple miRNA species with the 3'-UTR of a transcript 70.  
In the case of vascular endothelial growth factor (VEGFA), multiple distinct binding sites 
were observed in the 3’-UTR. Transfection with varying combinations of miRNAs 
resulted in additive levels of translational repression. VEGFA was the third most highly 
connected protein in our prostate cancer miRNA target network (Table 2-2).  
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Table 2-3: MicroRNA target connectivity changes with the role of the miRNA 
Description Number of Nodes 
Regulated by miRNA 
Type 
Node Degree 
OncomiR 
 (Expression increases during 
tumorigenesis) 
192 39 
Tumor Suppressor 
(Expression decreases during 
tumorigenesis) 
276 27 
Both 
(Exhibits both behaviors dependent 
upon a second variable) 
37 61 
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Figure 2-4: Proteins regulated by multiple miRNAs are more likely to be highly  
connected 
 
 
Proteins were grouped according to the number of miRNAs that have been proven to 
regulate their translation. The number of miRNAs that regulate a protein (independent 
variable) was plotted against the average node degree of the targets (dependent variable) 
and a best fit linear equation was generated (y = 17.91 x - 7.9; r2= 0.831).  Proteins that 
were regulated by 6-10 miRNA species were grouped into a single group because there 
were only a few proven examples regulated by more than 6 miRNAs. 
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Figure 2-4: Proteins regulated by multiple miRNAs are more likely to be highly  
connected 
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 Although not included in table 2-2, another example of a highly connected protein 
under multiple miRNA regulation is the cyclin dependent kinase inhibitor 1A (CDKN1A). 
CDKN1A was regulated by the largest number of unique miRNAs (28) and connects to 
190 other proteins 71. Many tumor suppressor pathways are under the control of 
CDKN1A and its decreased expression increases the likelihood of cancer development 72. 
As a potent cell proliferation inhibitor, CDKN1A is an important modulator of the cyclin 
dependent kinases (CDK) that regulate cell cycle progression through the G1/S 
checkpoint. Loss of the CDK inhibitor allows the cell to proceed through the cell cycle 
and diminishes the cell’s response to DNA damage. Increased expression of any of the 
miRNAs that regulate CDKN1A would decrease protein levels and induce oncogenic 
transformation. This analysis showed that important proteins were regulated by multiple 
miRNAs and dysregulation of any of these miRNAs could result in a disease state such as 
cancer.  
 
MiRNAs preferentially regulate highly connected transcription factors 
 Trans acting factors such as transcription factors and miRNAs control 
levels of proteins in the cell. However, each differs in their mode of regulation. 
Transcription factors typically bind up stream of a gene and either potentiate or inhibit 
transcription. miRNAs have been shown to preferentially bind the 3’ UTR of the mRNA 
transcript affecting protein translation through several mechanisms. Transcription factors 
that are targeted by miRNAs dysregulated during prostate cancer progression are more 
highly connected than randomly chosen transcription factors (p-value <0.001) (Figure 2-
5). This analysis identifies another mechanism of miRNA regulation. By targeting highly 
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connected transcription factors, miRNAs can exert a great influence over a large number 
of proteins. For example, SP1 is one of the most highly connected proteins in our 
network with a connectivity of 269.  
 
Summary  
Cancer is a multifactorial disease that arises from the accumulation of genetic and 
epigenetic changes that lead to oncogenic transformation causing cells to proliferate 
uncontrollably. MiRNAs are an important class of translational regulatory agents that 
affect cell proliferation, differentiation, cell cycle control, and apoptosis. Increased 
expression of oncomiRs or decreased expression of tumor suppressors leads to 
uncontrolled cell proliferation, invasion and metastasis.  
Because of the scale free design of complex systems and a higher average node 
degree, miRNA protein targets are more vulnerable to targeted attacks that may lead to 
catastrophic cellular failures 46. A single dysregulated miRNA has the potential to induce 
a significant number of cellular changes by affecting multiple highly connected proteins. 
It is important to consider that modulation of a single highly connected protein node has 
the potential to affect hundreds of downstream targets thereby modifying multiple 
pathways resulting in considerable physiological fluctuation. During the development of 
prostate cancer, there is wide scale dysregulation of miRNA expression affecting 
numerous highly connected, essential disease causing proteins and numerous cellular 
pathways (Figure 2-6).  
 By combining knowledge of miRNA dysregulation with topological descriptors 
of a protein-protein interaction network, we may identify important proteins contributing 
  - 44 -
to tumor progression that have not been previously described. This analysis will be used 
to identify newer, more relevant indicators of prostate cancer and may offer insights 
toward the development of targeted molecular therapies. These methods will be used to 
biologically evaluate the role of miRNA dysregulation in cell lines and human samples.   
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Figure 2-5: Connectivity of transcription factors 
Transcription factors were compiled from the TFCAT curated catalog of transcription 
factors 55. Transcription factors targeted by miRNAs dysregulated during tumorigenesis 
of the prostate were compiled by intersecting the list of miRNA targets with the table of 
transcription factors using PERL. The process was repeated using the list of randomly 
associated proteins. Data are presented as a whisker plot that was generated using R and a 
table of associated values.  
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Figure 2-5: 
 
Network Type Number
(467)  
Mean 
connectivity
Standard 
Deviation
Min Max 
miRNA targeted  112 
(24%) 
46.01 60.45 1 269 
Randomly chosen 122 
(26%) 
4.34 4.15 1 24 
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Figure 2-6: Model of miRNA regulation 
 
Figure 2-6: Model of miRNA regulation 
Using the data obtained from the systems level network analysis a model of miRNA 
regulation of prostate cancer was created.  
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Chapter 3 
 
 
Identification of dysregulated microRNAs contributing to prostate tumorigenesis 
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 Tightly controlled gene regulation is essential to every biological process. Failure 
to control gene regulation can result in cellular disease or death. Cells have devised many 
methods for regulating protein levels. The central dogma of biology of one gene, one 
mRNA, one protein as envisioned by Francis Crick is in need of modification.  Complex 
feedback loops involving RNA splicing, gene regulation at the transcriptional and 
translational level have been discovered. In order to understand a complex disease 
phenotype, researchers must consider a greater role for RNA than traditionally envisioned. 
In the past decade, microRNAs have emerged as an important class of post-
transcriptional regulators of protein levels. Nearly every biological process is under the 
control of at least one miRNA and it is thought that most protein levels are influenced by 
miRNA expression. Important highly interconnected proteins are often under the control 
of more than one miRNA 73.   
 Dysregulation of microRNA expression contributes to a number of pathological 
conditions and diseases including cancer of the prostate 22. Conversion of neoplastic 
growth from benign to metastatic dissemination is a step wise process that likely involves 
numerous biological macromolecules, often including RNA, protein, and DNA. 
Accumulating evidence suggests that multiple miRNAs are dysregulated during tumor 
formation, progression and metastasis 25. Both miRNA losses and gains of miRNA 
function have been shown to contribute to the development of neoplasm.  
 As previously discussed, miRNAs can function as either suppressors of tumor 
formation or promoters of tumorigenesis (oncomiRs). The increased expression of 
oncomiRs or loss of tumor suppressors can induce neoplastic transformation. It has been 
shown that over one hundred miRNAs are dysregulated during the development of 
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prostate cancer 73. Comparison of high throughput analyses of miRNA expression in the 
poorly tumorigenic, non-metastatic P69 cell line and its highly tumorigenic, metastatic 
variant M12 variant can reveal miRNAs that may contribute to tumorigenicity. As we 
have shown, miRNAs preferentially regulate highly connected protein targets.  
 In this study, we propose that our unique combinatorial approach will reveal 
dysregulated miRNAs contributing to carcinogenesis. Utilizing a prostate cancer cell 
progression model, we will determine potential miRNAs that may contribute to a 
cancerous phenotype. Dysregulated miRNAs will be ranked using a unique networks 
based approach and expression differences will be confirmed by single miRNA analysis. 
Expression of proposed dysregulated miRNAs will be evaluated using RNA extracted 
from pure cell populations obtained by LCM in order to validate differential expression 
from benign to tumorigenic epithelium. The contribution of these miRNAs to controlling 
P69 and/or M12 cell behavior will be further investigated by a variety of in vitro 
experiments. 
  
Materials and Methods   
Cell culture  
 Cells are cultured at 37° C in RPMI1640 with L-glutamine obtained from Gibco 
supplemented with 5% fetal bovine serum, 5μg/ml insulin, 5μg/ml transferrin, and 5 
μg/ml of selenium (ITS from Collaborative Research Bedford, MA). Inhibition of 
bacterial contamination was accomplished with the addition of Gentamycin (0.05mg/ml). 
M12 cells stably transformed with the p-SIREN (M12+miR-17-3p and M12+miR-125b) 
vector were maintained with Puromycin (100 ng/ml). F6 cells were maintained with 
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Geneticin (200 μg/ml) 24. All tissue culture cells were grown in T75 flasks and split when 
confluent. Cells were pelleted after trypsin (0.25% in EDTA) digestion by centrifugation 
at 5000 RPM for five minutes. Trypsin inactivated by washing the cells in serum 
containing media. After washing, cell pellets were flash frozen in liquid nitrogen after 
washing and stored for at least 24 hours.  
 
Cell pellet RNA extraction 
 Total RNA was extracted from cell pellets described above using the miRVana™ 
miRNA isolation kit from Ambion per manufacturer’s instructions.  Briefly, after cell 
lysis total RNA was bound to a glass fiber filter and eluted with a proprietary elution 
buffer. After isolation, RNA concentration was estimated using a Biorad® Smart Spec™ 
3000 spectrophotometer, diluted to a concentration of 100ng/ml and stored at -80°C for at 
least 24 hours.  
 
MicroRNA profiling 
 Real time PCR profiling was performed using the miRCURY LNA ™ Universal 
RT microRNA PCR system (Exiqon, Denmark). Human Panel I was used to identify 
dysregulated miRNAs in the P69 cell line versus its metastatic derivative M12. Duplicate 
samples were compared using 25ng and 50 ng of RNA as input. Briefly, RNA input was 
converted to cDNA using supplied reagents and enzymes (4μl of 5x reaction buffer, 9μl 
of nuclease free water, 2μl enzyme mix, 1μl synthetic RNA spike in, and 5 μl of RNA 
diluted to 5 ng/ul). The reaction was incubated for 60 minutes at 42° C and the enzyme 
was heat inactivated for 5 minutes at 95°C. Real time PCR plates were run on an 
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ABI7900 HT (95°C for 10 mins, 40 cycles at 95°C-10sec, 60°C-1 min, ramp rate 
1.6°C/s). Threshold and baseline were set manually according to recommendations in the 
supplied protocol. After correcting for interplate variability, cycle threshold (CT) values 
were normalized to the global mean of all miRNA expression. Initial data analysis was 
performed using Exiqon GenEx software and all values are reported as fold changes 
relative to P69. miRNAs exhibiting greater than 2-fold expression differences in both sets 
of arrays were considered to be significant and selected for further analysis.  
 
Ranking of dysregulated miRNAs 
 Significantly dysregulated miRNAs were ranked according to the sum network 
connectivity of proven targets. Proven targets of miRNAs were obtained by combining 
miRecords and Tarbase into a single non-redundant list. A protein-protein interaction 
network was inferred by using each targeted protein as a search term in the Agilent 
literature search (v2.76) tool implemented in Cytoscape 2.8 52, 53. Network properties 
were developed using CentiScape. 54.  
 
TaqMan® based miRNA assay   
 Verification of mature miRNA expression was confirmed using single assays by 
TaqMan® miRNA assay (Life Technologies, Grand Island, NY). Briefly, cDNA was 
synthesized in a 25μl reaction volume from 20 ng of total RNA using the TaqMan® 
MicroRNA Reverse Transcription kit. Reactions were incubated at 16°C for 30 minutes, 
42°C for 30 minutes and inactivated at 85°C for 5 minutes. Each cDNA was analyzed in 
triplicate by quantitative PCR using sequence specific primers in an ABI7300 qRT PCR 
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system (Applied Biosystems). Each individual assay was performed in a 20μl reaction 
volume with 1.33μl of cDNA, 1.0μl specific miRNA assay, 10μl TaqMan™ Universal 
PCR Master Mix II with no AMP Unerase and 7.67μl of nuclease free water. Reactions 
were incubated in a 96 well plate at 50°C for 2 minutes, followed by 95°C at 95°C and 40 
cycles of 95°C for 15 sec/ 60°C for 60 sec.  
 
SYBR green based qRT-PCR 
 Quantification of mature miRNA expression was carried out using the miRCURY 
LNA™ Universal RT miRNA PCR (Exiqon, Denmark). Synthesis of cDNA was 
accomplished by incubating 50ng of total RNA in a 20μl reaction volume of 5X reaction 
buffer (4μl), nuclease free water (9μl), enzyme mix (2μl), synthetic RNA control spike in 
(1μl) and template RNA (4μl). cDNA reaction was incubated for 60 minutes at 42°C and 
enzyme inactivated for 5 minutes at 95°C. Following synthesis, the cDNA is diluted 20 
fold with nuclease free water. Real time PCR amplification was performed in a 10μl 
reaction with 4μl of diluted cDNA template, 5μl SYBR® Green Master Mix (Exiqon, 
Denmark), and 1 μl of PCR primer mix. The reaction was run in an ABI 7300 (Applied 
Biosystems) at 95°C for 10 min, followed by 40 cycles of 95°C (10 sec), 60°C (60 sec) at 
a ramp rate of 1.6°C/sec. Melt curve analyses were run on each reaction to verify single 
product amplification. Threshold and baseline were set manually according to 
recommendations in the supplied protocol. 
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qRT-PCR data analysis  
 Relative quantities of miRNA levels were determined using the 2-ddCT method of 
Livak et al after normalization with RNU48 as a standard reference 74.  All samples were 
performed in triplicate and the average cycle threshold (CT) value was determined. The 
average CT was normalized by subtracting the average CT of RNU48 (dCT). All samples 
were compared to the parental P69 cell line by subtracting the experimental dCT from the 
dCT value of the parental cell line (calibrator).  
 
Laser capture microdissection 
 Human prostate samples were obtained from frozen core samples of radical 
prostatectomy samples available from VCU’s Tissue and Data Acquisition and Analysis 
Core. All samples were obtained with approval from the VCU institutional review board. 
All slides were reviewed by a board certified pathologist with expertise in prostate cancer 
diagnosis. Briefly, 8 μm tissue slices were placed on uncharged glass slides, dehydrated 
with progressively increasing concentrations of ethanol, stained with hematoxylin and 
eosin (H&E). Laser capture microdissection was performed using an Arcturus Veritas 
machine. Areas of interest were captured onto CapSure® Macro LCM caps (Life 
Technologies, Grand Island, NY).  At least ten slides were captured for each patient 
included in the study.  
 
RNA extraction of LCM samples 
 Total RNA was extracted from LCM extracts using the PicoPure® RNA Isolation 
Kit (Life Technologies, Grand Island, NY). The manufacturer’s protocol was followed. 
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Following dissection of tissue, the LCM caps were incubated for 30 minutes at 42°C in 
50μl of extraction buffer. Cell extracts were stored at -20°C until ready for RNA 
extraction. Similar cellular lysates from successive slides were pooled into a single tube 
and mixed with 1 volume of ethanol (70%).  The lysate/ethanol solution was loaded onto 
a high recovery MiraCol™ column and centrifuged at 100xg for 2 minutes followed by 
16,000xg for 30 seconds. RNA was recovered in an 11μl volume. Concentration and 
quality were measured using an Agilent RNA 6000 Pico kit with the Agilent Bioanalyzer 
2100. 
Cloning of miR-125b into M12 cells 
M12 cells (500,000) were stably transformed with the human miR-125b sequence (as 
underlined) 5’-
GATCCGTCCCTGAGACCCTAACTTGTGATGTTTACCGTTTAAATCACAAGTTA
GGGTCTCAGGGA TTCTTTTTTTCTAGAG-3’ and its complement 5’-
AATTCTCTAGAAAAAAAGAATCCCTGAGACCCTAACTTGTGATTTAAACGGT
AAACATCACAAGTTAGGGTCTCAGGGACG-3’ into the BamHI and EcoRI cloning 
sites of the pSIREN vector (BD Biosciecnes, SanJose, CA). Cells were transformed with 
purified plasmid (2.0 μg) using TransIT-LT1 (4.0 μl) transfection reagent (Mirus 
BioCorp, Madison, WI). Resistant cells were selected with 400 ng/ml Puramycin. 
 
Migration assay  
 Cells were detached from the plate using 2.0 ml of CellStripper™ (CellGro®, 
Manassas, VA) and pelleted at 5000 rpm for 5 minutes.  Cells were washed in serum free 
RPMI 1640 and re-suspended in serum free media at a concentration of 2.5x105cells/ml. 
  - 56 -
200 μl of cell suspension (50,000 cells) was added to the top chamber of a 6.0μm pore 
size ThinCert™ tissue culture insert (Greiner, Monroe, NC). 0.5 ml of serum containing 
media was added to the lower chamber supplemented with 10 ng/ml of EGF (Figure 3-1 
A). Cells were incubated at 37°C for 20 hours. Media was removed from both chambers 
and cells were fixed in 0.025% glutaraldehyde in PBS for 20 minutes after removal of all 
media from both chambers. Following fixation, inserts were stained with 0.1% crystal 
violet in PBS for 30 minutes and washed with sterile deionized water. Non-migratory 
cells were removed from the top surface with a sterile cotton applicator and inserts 
mounted on a glass microscope slide. Cells were counted in 10 random fields at a 200 X 
magnification. Data are presented as the mean sum of migratory cells in 10 random fields  
± standard error.  
 
Invasion assay 
 Invasion assays are carried out in a manner similar to the migration assays. At 
least 30 minutes prior to extracting cells, 60 μl (diluted 1:10) of Culturex® reduced 
growth factor basement membrane is added to the top chamber of the ThinCert™ tissue 
culture insert and incubated at 37°C for gelling (Figure 3-1 B). After ensuring that the 
basement membrane has gelled, the remainder of the protocol is identical to the migration 
assay. Data are presented as the mean sum of invasive cells in 10 random fields  ± 
standard error.  
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Figure 3-1: Migration and invasion assay 
 
Figure 3-1: Migration and invasion assay 
A. Illustration of the experimental setup for an individual well migration assay.  
B. Illustration of the experimental setup for an individual well invasion assay.  
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Results  
 
Identification of miRNAs dysregulated during tumorigenesis 
 Understanding the molecular perturbations that underlie cancer initiation, 
progression and metastasis are critical to identify newer, more relevant biomarkers. Many 
model cell lines have been used to explore prostate cancer progression. Most are derived 
from metastatic sites and thus may not represent the best model for elucidation of early 
indicators of cancer formation 75-77 . Rather than being isolated from a metastatic site, 
these cells were obtained from normal prostate tissue immortalized with SV40 large T 
antigen (P69) and cycled through male athymic nude mice to obtain the tumorigenic 
variant (M12) discussed earlier 23. This unique isogenic model may provide insights to 
the molecular causes that initiate cancer formation.  
 Quantification of miRNA levels is difficult. The length of the mature miRNA is 
22-23 nucleotides, the same length as traditional PCR primers. Increasing the difficulty is 
the fact that often miRNAs only differ from one another by a single base. Thus, it is very 
difficult to design a primer that can discriminate single base differences in such small 
molecules. The advent of locked nucleic acid (LNA™) modified primers increases the 
specificity and sensitivity of qRT-PCR for miRNAs.  
 Utilizing a LNA™ based array panel that profiles the most relevant,  currently 
identified miRNAs (386 miRNAs), we discovered 180 miRNAs that significantly change 
at least two-fold from the parental P69 cell line to the highly tumorigenic M12 cell line 
(Table 3-1). Eighty six miRNAs were lost as the tissue becomes more 
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 Table 3-1: miRNAs dysregulated during tumorigenesis  
 
microRNA Fold Difference  Behavior 
hsa-miR-125b 4.76E-06 Tumor Suppressor 
hsa-miR-500 0.001 Tumor Suppressor 
hsa-miR-127-3p 0.002 Tumor Suppressor 
hsa-miR-382 0.003 Tumor Suppressor 
hsa-miR-411 0.004 Tumor Suppressor 
hsa-miR-299-5p 0.004 Tumor Suppressor 
hsa-miR-576-5p 0.004 Tumor Suppressor 
hsa-miR-620 0.008 Tumor Suppressor 
hsa-miR-409-3p 0.008 Tumor Suppressor 
hsa-miR-144 0.012 Tumor Suppressor 
hsa-miR-410 0.013 Tumor Suppressor 
hsa-miR-548c-3p 0.014 Tumor Suppressor 
hsa-miR-136 0.015 Tumor Suppressor 
hsa-miR-323-3p 0.015 Tumor Suppressor 
hsa-miR-379 0.018 Tumor Suppressor 
hsa-miR-583 0.026 Tumor Suppressor 
hsa-miR-377 0.031 Tumor Suppressor 
hsa-miR-539 0.034 Tumor Suppressor 
hsa-miR-487b 0.035 Tumor Suppressor 
hsa-miR-376c 0.036 Tumor Suppressor 
hsa-miR-325 0.042 Tumor Suppressor 
hsa-miR-135b 0.045 Tumor Suppressor 
hsa-miR-337-5p 0.054 Tumor Suppressor 
hsa-miR-598 0.056 Tumor Suppressor 
hsa-miR-99a* 0.061 Tumor Suppressor 
hsa-miR-432 0.062 Tumor Suppressor 
hsa-miR-20b 0.064 Tumor Suppressor 
hsa-miR-597 0.068 Tumor Suppressor 
hsa-miR-135a 0.068 Tumor Suppressor 
hsa-miR-183 0.072 Tumor Suppressor 
hsa-miR-15b 0.079 Tumor Suppressor 
hsa-miR-509-3p 0.080 Tumor Suppressor 
hsa-miR-376a 0.086 Tumor Suppressor 
hsa-miR-19a 0.091 Tumor Suppressor 
hsa-miR-495 0.098 Tumor Suppressor 
hsa-miR-223 0.111 Tumor Suppressor 
hsa-miR-198 0.114 Tumor Suppressor 
hsa-miR-302b 0.114 Tumor Suppressor 
hsa-miR-185* 0.115 Tumor Suppressor 
hsa-miR-346 0.116 Tumor Suppressor 
hsa-miR-425* 0.119 Tumor Suppressor 
hsa-miR-886-3p 0.134 Tumor Suppressor 
hsa-miR-891a 0.138 Tumor Suppressor 
hsa-miR-212 0.148 Tumor Suppressor 
hsa-miR-514 0.149 Tumor Suppressor 
hsa-miR-383 0.150 Tumor Suppressor 
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microRNA Fold Difference Behavior 
hsa-miR-493 0.153 Tumor Suppressor 
hsa-miR-342-3p 0.160 Tumor Suppressor 
hsa-miR-187* 0.168 Tumor Suppressor 
hsa-miR-631 0.174 Tumor Suppressor 
hsa-miR-369-5p 0.182 Tumor Suppressor 
hsa-miR-449a 0.191 Tumor Suppressor 
hsa-miR-185 0.209 Tumor Suppressor 
hsa-miR-100 0.209 Tumor Suppressor 
UniSp6 CP 0.224 Tumor Suppressor 
hsa-miR-214 0.242 Tumor Suppressor 
hsa-miR-127-5p 0.252 Tumor Suppressor 
hsa-miR-572 0.259 Tumor Suppressor 
hsa-miR-21 0.260 Tumor Suppressor 
hsa-miR-146a 0.264 Tumor Suppressor 
hsa-miR-134 0.271 Tumor Suppressor 
hsa-miR-302c* 0.280 Tumor Suppressor 
hsa-miR-625* 0.287 Tumor Suppressor 
hsa-miR-27a 0.300 Tumor Suppressor 
hsa-miR-296-5p 0.309 Tumor Suppressor 
hsa-miR-335 0.316 Tumor Suppressor 
hsa-miR-376b 0.321 Tumor Suppressor 
hsa-miR-31 0.323 Tumor Suppressor 
hsa-miR-525-5p 0.341 Tumor Suppressor 
hsa-miR-191 0.349 Tumor Suppressor 
hsa-miR-196b 0.350 Tumor Suppressor 
hsa-miR-654-5p 0.365 Tumor Suppressor 
hsa-miR-187 0.370 Tumor Suppressor 
hsa-miR-339-5p 0.371 Tumor Suppressor 
hsa-miR-720 0.374 Tumor Suppressor 
hsa-miR-140-3p 0.392 Tumor Suppressor 
hsa-miR-146b-5p 0.394 Tumor Suppressor 
hsa-miR-181b 0.409 Tumor Suppressor 
hsa-miR-506 0.409 Tumor Suppressor 
hsa-miR-30b 0.416 Tumor Suppressor 
hsa-miR-629 0.426 Tumor Suppressor 
hsa-miR-203 0.452 Tumor Suppressor 
hsa-miR-449b 0.459 Tumor Suppressor 
hsa-miR-27b 0.463 Tumor Suppressor 
hsa-let-7a 0.480 Tumor Suppressor 
hsa-miR-138 0.490 Tumor Suppressor 
hsa-miR-298 2.0 OncomiR 
hsa-miR-665 2.1 OncomiR 
hsa-miR-126* 2.1 OncomiR 
hsa-miR-152 2.1 OncomiR 
hsa-miR-423-5p 2.2 OncomiR 
hsa-miR-502-5p 2.2 OncomiR 
hsa-miR-151-5p 2.2 OncomiR 
hsa-miR-324-5p 2.2 OncomiR 
hsa-miR-576-3p 2.3 OncomiR 
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microRNA Fold Difference Behavior 
hsa-miR-330-3p 2.3 OncomiR 
hsa-miR-302a 2.4 OncomiR 
hsa-miR-7 2.4 OncomiR 
hsa-let-7c 2.5 OncomiR 
hsa-miR-615-3p 2.6 OncomiR 
hsa-miR-933 2.6 OncomiR 
hsa-miR-148a 2.6 OncomiR 
hsa-let-7d 2.6 OncomiR 
hsa-miR-22 2.7 OncomiR 
hsa-miR-33a 2.7 OncomiR 
hsa-miR-450a 2.7 OncomiR 
hsa-miR-210 2.7 OncomiR 
hsa-miR-29c 2.7 OncomiR 
hsa-miR-491-5p 2.8 OncomiR 
hsa-miR-365 2.8 OncomiR 
hsa-miR-30d 2.8 OncomiR 
hsa-miR-545 2.8 OncomiR 
hsa-miR-602 2.9 OncomiR 
hsa-miR-589 2.9 OncomiR 
hsa-miR-148b 2.9 OncomiR 
hsa-miR-374a 2.9 OncomiR 
hsa-miR-668 3.0 OncomiR 
hsa-miR-431 3.1 OncomiR 
hsa-miR-200a 3.1 OncomiR 
hsa-miR-130b 3.2 OncomiR 
hsa-miR-32 3.3 OncomiR 
hsa-miR-10a 3.3 OncomiR 
hsa-miR-204 3.4 OncomiR 
hsa-miR-22* 4.1 OncomiR 
hsa-miR-486-5p 4.2 OncomiR 
hsa-miR-326 4.4 OncomiR 
hsa-miR-30c-2* 4.5 OncomiR 
hsa-miR-96 4.7 OncomiR 
hsa-miR-371-5p 4.7 OncomiR 
hsa-miR-181c 4.7 OncomiR 
hsa-miR-518e 5.0 OncomiR 
hsa-miR-10b 5.2 OncomiR 
hsa-miR-188-5p 5.3 OncomiR 
hsa-miR-642 5.8 OncomiR 
hsa-miR-99a 6.1 OncomiR 
hsa-miR-130a 6.4 OncomiR 
hsa-miR-888 6.5 OncomiR 
hsa-miR-890 7.2 OncomiR 
hsa-miR-608 7.8 OncomiR 
hsa-miR-370 8.0 OncomiR 
hsa-miR-338-3p 8.3 OncomiR 
hsa-miR-1 8.5 OncomiR 
hsa-miR-518a-3p 8.6 OncomiR 
hsa-miR-497 8.7 OncomiR 
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microRNA Fold Difference Behavior 
hsa-miR-595 9.5 OncomiR 
hsa-miR-124 9.5 OncomiR 
hsa-miR-9 9.6 OncomiR 
hsa-miR-301b 10.7 OncomiR 
hsa-miR-381 10.9 OncomiR 
hsa-miR-570 11.3 OncomiR 
hsa-miR-518b 11.6 OncomiR 
hsa-miR-139-5p 11.7 OncomiR 
hsa-miR-196a 12.8 OncomiR 
hsa-miR-662 13.2 OncomiR 
hsa-miR-105 13.4 OncomiR 
hsa-miR-516a-5p 13.6 OncomiR 
hsa-miR-873 14.6 OncomiR 
hsa-miR-596 14.9 OncomiR 
hsa-miR-517a 15.9 OncomiR 
hsa-miR-199a-3p 16.5 OncomiR 
hsa-miR-217 20.1 OncomiR 
hsa-miR-518c* 20.3 OncomiR 
hsa-miR-211 26.0 OncomiR 
hsa-miR-299-3p 27.5 OncomiR 
hsa-miR-33b 29.9 OncomiR 
hsa-miR-491-3p 37.8 OncomiR 
hsa-miR-498 51.4 OncomiR 
hsa-miR-147 54.2 OncomiR 
hsa-miR-373* 59.2 OncomiR 
hsa-miR-517c 68.4 OncomiR 
hsa-miR-451 68.5 OncomiR 
hsa-miR-133b 68.9 OncomiR 
hsa-miR-524-3p 85.7 OncomiR 
hsa-miR-133a 92.9 OncomiR 
hsa-miR-551b 152.2 OncomiR 
hsa-miR-375 191.0 OncomiR 
hsa-miR-153 240.0 OncomiR 
hsa-miR-622 365.0 OncomiR 
hsa-miR-147b 522.1 OncomiR 
hsa-miR-34a 1850.8 OncomiR 
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tumorigenic, that is they function as potential suppressors of tumor formation. The 
average expression difference of all tumor suppressors is 100-fold i.e. they are 100-fold 
higher in the P69 cell line compared to the M12 variant. Expression of the remaining 94 
dysregulated miRNAs increases as the tumorigenicity increases (oncomiRs). OncomiRs 
have an average of 45-fold difference when compared to the P69 cells. The overall 
number of tumor suppressors and oncomiRs is similar to that found using our global 
networks approach where we found approximately as many tumor suppressors as 
oncomiRs. Interestingly, the average connectivity of an oncomiR target is higher than the 
average target of tumor suppressor miRNAs (Table 2-3). It is reasonable to hypothesize 
that greater miRNA fold changes are needed to induce phenotypic alterations if the 
targets are not as highly connected.  
 Human miR-125b is the most dysregulated tumor suppressor and is essentially 
lost in the M12 cells. Conversely, hsa-miR-34a is much greater in the M12 cells 
compared to the P69 cells. As discussed in chapter 2, the miR2disease database lists 111 
miRNAs that have been experimentally shown to contribute to the development of 
prostate cancer 48. In our model system, 76 of the 111 miRNAs in miR2disease are 
dysregulated. This suggests that our cell progression model is a relevant indicator of 
prostate cancer progression and may be useful to assess which miRNAs are causative to 
prostate cancer and serve as useful biomarkers. 
 Microarray technology has increased the ability of researchers to simultaneously 
profile thousands of molecules at a single time point. Because of their power, microarrays 
have become popular tools among molecular biologists. Important considerations when 
evaluating array based studies are the validity of the results, and universality of findings 
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78. Repeat experiments are critical to eliminate noise in data. In this study, we profiled 
two cell lines in duplicate. All miRNAs reported in Table 3-1 were found to be 
significantly dysregulated in both sets of arrays. The primary goal of microarray analyses 
is to accurately identify differential molecular regulation affecting biological processes. It 
is essential that identified miRNAs be validated using traditional techniques such as qRT-
PCR. Studies have shown that 71% of mRNAs identified to be dysregulated using 
microarray were confirmed using qRT-PCR assays 79. However, the fold difference does 
not always replicate. This finding suggests that array based methods are valid as 
screening tools but true expression differences are only accurate using a single assay 
format.  
 
Network properties for ranking microRNA dysregulation 
 The cost to confirm every potentially dysregulated miRNA identified in a 
microarray experiment is prohibitively expensive. Few labs have the financial or physical 
resources needed to carry out such validation. Therefore, most labs choose a subset of 
genes, proteins, or miRNAs to validate. Many factors affect the choice of a gene set 
including relative difference, biological function, availability of reagents, and investigator 
preference. A traditional approach has been to prioritize molecules with the greatest 
expression difference as such expression differences are more likely to validate 78.   
 This approach may overestimate the importance of differential expression. It is 
reasonable to suspect that smaller changes in some miRNAs may exert a greater 
influence in tissue behavior, if they modulate the expression of more important proteins.  
Indeed, our analysis has shown a preference for miRNAs to regulate highly connected 
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protein nodes (Figure 2-6). Thus a single dysregulated miRNA can affect hundreds of 
downstream targets by affecting the level of one highly connected protein. In this study 
we chose a subset of genes for further studies using network properties for proven targets 
of each miRNA. A total of eight miRNAs were chosen for validation based on their sum 
network connectivity (Table 3-2).  
 Dysregulated miRNAs with a range of connectivity indices were chosen (20-
1330). Interestingly, two of the miRNAs with the highest connectivity index, were also 
the two most differentially expressed miRNAs (hsa-miR-125b and hsa-miR-34a). Three 
miRNAs chosen had a sum connectivity of over 1000 each. When multiple highly 
connected miRNAs are dysregulated there is a great potential to affect many signaling 
pathways simultaneously. Hsa-miR-1 has the highest connectivity of all miRNAs in our 
analysis, potentially influencing 1330 downstream targets. Again, it is important to re-
iterate that this index reflects a global potential. It is unlikely that all 1330 proteins are 
affected at the same time due to both differential protein and miR expression in various 
cell types. Instead, proteins will interact with one another in a variety of conditions.   
 Expression profiles comparing levels in M12 and P69 cells of each chosen 
miRNA were determined using the ddCT method by Livak et al. Based on array results, 5 
of the miRNAs chosen seem to function as oncomiRs (Figure 3-2). Their expression is 
higher in the highly tumorigenic, metastatic M12 cell line. As mentioned previously, 
miR-34a is the most dysregulated oncomiR. Its expression is approximately 1800 times 
higher in the M12 cell line than it is in the P69 cell line. The sum connectivity of proven 
protein targets of miR-34a is 1208. As the expression change is quite dramatic, and the 
connectivity of its targeted proteins is very high, it is reasonable to suspect that 
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Table 3- 2: Subset of miRNAs chosen for further validation  
 
microRNA Targets Degree 
hsa-miR-375 
 Mxi1 Ahr C1QBP  YAP JAK2  ADIPOR2  YWHAZ 
Insm1 USP1 XBP-1 MTPN  20 
hsa-miR-127-3p * BLIMP-1, BCL6 52 
hsa-miR-200a 
ERBB2IP, ZEB1, ZEB2, ELMO2, SIP1 and 7 
others 56 
hsa-miR-146a * 
CDKN3, BRCA1, MCM10, IRF-5, ROCK1and 
others 504 
hsa-miR-22  PTEN ESR1 BMP7 PPARA MAX 565 
hsa-miR-125b * 
DICER, ERBB2, ERBB3, CDKN2A, BAK1, UBE21, 
LIN28, ID3, and others 1194 
hsa-miR-34a 
CYCLIN D1 BCL2 CCND1 WNT1 E2F3 NOTCH2 
MYCN Delta1 CDK6 SIRT1 VEGF c-MET MEK1 
AXIN2 MYB JAG1 MYC NOTCH-1 1208 
hsa-miR-1 
TPM3, PIM-1, HDAC4, c-MET, TPM1, PARG1 and 
others 1330 
 
*- potential tumor suppressors  
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Figure 3-2: Differential expression of oncomiRs determined using Exiqon’s 
miRCURY human panel I 
A profile of the miRnome was obtained using the miRCURY ready to use PCR human 
panel I, V2 (Exiqon, Denmark). The experiment was run in duplicate using 20 and 50 ng 
RNA as starting material. Manufacturer’s protocol was followed and data are presented 
as the mean expression fold difference of M12 compared to P69. Positive numbers 
represent an increased expression in M12 cells. Error bars represent the standard 
deviation of fold changes between the two duplicate assays. Note the broken y axis to 
depict the discrepancy between miR-22 to miR-34a better. 
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Figure 3-2: Differential expression of oncomiRs determined using Exiqon’s 
miRCURY human panel I 
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dysregulation of miR-34a may induce an oncogenic event. Even though miR-1 is only 8- 
fold higher in M12, it is likely to have a great effect on the tumorigenic properties of the 
cell as it targets a large number of highly connected proteins.  
 Three of the miRNAs chosen for validation from the array seem to function as 
tumor suppressors (Figure 3-3). miR-125b is several thousand fold higher in the non-
tumorigenic parental cell line (P69). Its expression is nearly undetectable in the M12 
subline. HSA-miR-146a is the least differentially expressed tumor suppressor included in 
our study. Its level is nearly four times higher in the P69 cells.  
 An additional miRNA was chosen to be validated not because of its connection to 
the network, but because of other biological interests. miR-127-5p is an alternative 
transcript that comes off of the same precursor as miR-127-3p. 80. Many miRNAs have 
the ability to produce two functional miRNAs from the same pre-miRNA 81. Although 
they are produced from the same precursor, miR-127-5p and miR-127-3p do not 
accumulate at equal levels in the cell. There appears to be a preference towards 
accumulation of miR-127-5p at the expense of miR-127-3p (Figure 3-4). Note the 
difference in y-axis scale between Figures 3-3 and 3-4.  In the latter figure log 
transformation was not used in order to optimize the display of differential expression 
between miR-127-5p and miR-127-3p.  
 
Validation of miRNA dysregulation using locked nucleic acid primers 
 Since the advent of qRT-PCR, there have been numerous improvements to the 
process. Several methods exist that allow quantification of the starting cDNA input.  
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Figure 3-3: Differential expression of tumor suppressors determined using Exiqon's 
human miRCURY screen panel I 
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Figure 3-3: Differential expression of tumor suppressors determined using Exiqon's 
human miRCURY screen panel  I. 
 
A profile of the miRnome was obtained using the miRCURY ready to use PCR human 
panel I, V2 (Exiqon, Denmark). The experiment was run in duplicate using 20 and 50 ng 
RNA as starting material. Manufacturer’s protocol was followed and data are presented 
as the log transformed mean expression fold difference of M12 compared to P69. Log 
transformation was used as to reflect the differences in expression. Negative numbers 
represent a decreased expression in M12 cells. Error bars represent the standard deviation 
of fold changes between the two duplicate assays. 
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Figure 3-4: Differential regulation of mature miRNAs produced by same pre-
miRNA using miRCURY screen panels 
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Figure 3-4: Differential regulation of mature miRNAs produced by same pre-
miRNA using Exiqon's human miRCURY screen panels 
Analysis of the levels of miR-127-5p and miR-127-3p obtained from profile of the entire 
miRnome. Data was obtained using the miRCURY ready to use PCR human panel I, V2 
(Exiqon, Denmark). The experiment was run in duplicate using 20 and 50 ng RNA as 
starting material. Manufacturer’s protocol was followed and data are presented as the 
mean expression fold difference of M12 compared to P69. Values less than 1 represent an 
decreased expression in M12 cells. Error bars represent the standard deviation of fold 
changes between the two duplicate assays. 
 
  - 72 -
SYBR green is a DNA intercalating agent that fluoresces when bound to double-stranded 
DNA 82. In a qRT-PCR reaction it serves as a reporter and its fluorescence increases 
exponentially with each cycle of the reaction. The amount of input material is quantified 
once the reporter activity exceeds an arbitrary threshold (Cycle Threshold, CT). CT 
values decrease linearly as the amount of starting material is increased. Thus, a sample 
with more starting material will display a lower CT value. 
 LNA™ modified probes were used in this study to validate expression differences 
of the eight miRNAs chosen using our unique networks based approach plus the two 
additional miRNAs (miR-127-5p, miR-34b). All miRNAs chosen for validation are 
described by sequence and accession number in Table 3-3 as names often change as 
miRBase is updated.  
 Performance of LNA™ modified primers was verified using RNU48 and miR34a 
as a representative primer set (Figure 3-5). RNU48, traditionally used as a normalization 
standard, exhibited a linear decrease in CT values as the amount of starting material 
increased (r2=0.9985). Normalization is accomplished by subtracting the CT value of 
RNU48 from the raw CT value of the experimental probe (delta CT).  The delta CT of 
miR-34a decreases linearly as the amount of starting material increased (r2= 0.9986). As 
both LNA™ modified probes exhibited the expected linear decrease with extremely good 
correlation coefficients, it is reasonable to expect that all probes available from the 
manufacturer will perform in a similar manner. Exiqon advises that each of their primer 
sets have been validated to specifically bind only a single miRNA and demonstrates the 
same linear correlation as we observed for RNU48 and miR-34a. 
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Table 3- 3: Information and sequence for each profiled miRNA  
miRNA Sequence miR Base Accession Number 
hsa-miR-375    UUUGUUCGUUCGGCUCGCGUGA  MIMAT0000728  
hsa-miR-127-3p    UCGGAUCCGUCUGAGCUUGGCU  MIMAT0000446  
hsa-miR-127-5p    CUGAAGCUCAGAGGGCUCUGAU MIMAT0004604   
hsa-miR-146a     UGAGAACUGAAUUCCAUGGGUU MIMAT0000449   
hsa-miR-22     AAGCUGCCAGUUGAAGAACUGU MIMAT0000077  
hsa-miR-200a     UAACACUGUCUGGUAACGAUGU MIMAT0000682  
hsa-miR-1      UGGAAUGUAAAGAAGUAUGUAU MIMAT0000416 
hsa-miR-125b  UCCCUGAGACCCUAACUUGUGA MIMAT0000423 
hsa-miR-34b CAAUCACUAACUCCACUGCCAU  MIMAT0004676 
hsa-miR-34a UGGCAGUGUCUUAGCUGGUUGU  MIMAT0000255 
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Figure 3-5: Verification of locked nucleic acid probes  
RNA (20.0 ng) isolated from M12 cells was converted into cDNA using the miRCURY 
LNA™ Universal RT PCR system (Exiqon, Denmark). cDNA was diluted to an 
approximate concentration of 0.2 ng/μl, 0.4 ng/μl, and 0.8 ng/μl. Each reaction was 
performed in triplicate with individual LNA™ modified oligonucleotide primer sets and 
real time PCR amplification using SYBR Green. RNU48 was used as an endogenous 
standard (A). The experimental probe (miR-34a) was normalized by subtracting the 
corresponding CT value of RNU48 (B). Both plots compare CT values to the amount of 
starting material. 
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Figure 3-5: Verification of locked nucleic acid probes  
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 Cancer formation occurs in a step wise process beginning with initiation and 
ending at metastasis. Along the way, many factors affect and influence the development 
of cancer. MiRNAs, genes, proteins, and epigenetic mechanisms all contribute during 
each step of the process. It is important to identify the specific stages of cancer 
progression that each molecule affects. Utilizing our genetically related prostate cancer 
progression model, we assayed levels of each dysregulated miRNA in the P69, M2182, 
and the M12 cell lines. Each step in the progression model was described previously 
(Figure 1-4). As discussed, array based methods are useful for identifying trends in 
dysregulation, but true fold changes can only be detected using a single assay format. 
Results from microarry screens versus single miRNA analyses will be compared in the 
following section.  Where appropriate these results will be correlated to those reported in 
the literature. 
 
miR-22 
 Human miR-22 increased during the development of the M12 cells approximately 
4-fold (Figure 3-2). Single assay analysis confirms that miR-22 does indeed increase in 
the M12 subline when compared to the P69 cells (Figure 3-6). Interestingly, the bulk 
increase occurred during the early phases of tumorigenesis from P69 to M2182. There is 
only a slight increase in miR-22 from the M2182 cells to the M12 cells.  
 In the literature, cell lines derived from primary prostate tumor and from distant 
metastatic sites display increased levels of miR-22 83. DU145 cells stably transduced  
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Figure 3-6: Validation of oncomiRs using single assay format 
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Figure 3-6: Validation of oncomiRs using single assay format 
RNA (50ng) was reverse transcribed into cDNA using a universal RT PCR system 
(Exiqon, Denmark). Each assay was conducted in triplicate with an LNA modified 
oligonucleotide primer set. SYBR green was used as the fluorescent reporter and the PCR 
reaction was performed in an ABI7300. Data are presented as the mean fold change 
between each cell type relative to P69.    
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 with a retroviral vector expressing pri-miR-22 formed a higher number of colonies in 
soft agar as compared to a nonsense control. Increased expression of miR-22 negatively 
correlates with the level of PTEN (a known tumor suppressor). In situ hybridization on a 
prostate tumor microarray slide reveals a majority of prostate tumors express miR-22, 
while non-tumorigenic tissue does not. 
 The phosphatase and tensin homog (PTEN) represses the PI3K-AKT pathway 
which promotes proliferation, invasiveness, and motility 84. Mutations or deletions of 
PTEN are common and occur frequently in many cancers including CaP. Dosage-
dependent inactivation of PTEN effects tumor progression, invasion and latency. Subtle 
reductions in PTEN can increase tumorigenic propensity of cells and complete loss of 
PTEN often gives rise to an aggressive, metastatic phenotype. miR-22, along with other 
miRNAs, reduces the level of PTEN. Increased expression of miR-22 can lead to a 
decrease of PTEN levels and accelerate the PI3K/ AKT pathway. Altogether our results 
agree with these reported findings and support the importance of miR-22 to prostate 
cancer progression implicating it as a potential oncogenic miRNA.  
 
miR-200a 
 According to the profiling results, miRNA-200a increases in the M12 subline 
compared to the P69 cells. In a single assay format using LNA™ primers, we also 
observed an increase in miR-200a expression as tumorigenicity increased but to a higher 
level (13-fold) than what was observed in the array (Figure 3-6).  
 Conversely, most studies seem to find that miR-200a functions as a tumor 
suppressor with decreased expression upon tumor formation. Multiple studies have 
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shown that the miR-200 family is essential in maintenance of an epithelial phenotype 85, 
86. Loss of expression of miR-200a induces an epithelial to mesenchymal transition (EMT) 
through loss of ZEB1/ ZEB2 repression. The EMT is essential for a cell to detach from 
its neighbors and become motile. There are many markers that indicate a cell has 
undergone an EMT including increased expression of vimentin and  n-cadherin, nuclear 
localization of β-catenin and loss of e-cadherin 87.  
 However, there may exist opposite actions for miR-200a that are tumor or tissue 
type specific. For example, in endometrial endometroid carcinomas (EEC) there is 
significantly increased expression of all miR-200 family members 88. Specific inhibition 
of miR-200a in EEC cell lines decreases proliferation and growth. Although not 
statistically significant, Lin et al observed a tendency towards an increased expression of 
miR-200a in bladder cancer 89.  
 Interestingly, we observed a dramatic increase in the level of miR-200a in the 
highly tumorigenic and metastatic M12 cell line. There is a slight increase in the relative 
level of miR-200a in the intermediate M2182 cells. Expression of miR-200a 
exponentially increases from M2182 to the M12 cells which exhibit a more tumorigenic 
phenotype. Other work in our lab shows M12 cells to be highly invasive and motile 90. 
Along with the increased metastatic potential, there is decreased expression of e-cadherin, 
increased expression of vimentin and nuclear localization of β-catenin proving that M12 
cells have undergone an EMT switch.  
 On the surface, it appears that the results found in this study are contradictory. 
However, there are numerous targets of miR-200a and it is likely that additional targets 
remain to be discovered. Regulation of a single target by a miRNA is only partially 
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understood. It remains to be determined how a miRNA chooses its target when faced 
with dozens of possibilities. Sequence complementarity, free energy of binding, and 
mRNA levels may potentially influence which targets are regulated inside of a cell under 
various conditions. It is becoming clear that multiple types of miRNA interactions are 
common and it is unlikely that a single miRNA will always serve as either an oncomiR or 
tumor suppressor in all cell types. Due to this multiplicity of interactions, it is essential to 
dissect the role of miRNA dysregulation in context of specific types of cancer requiring 
additional experimentation. In this model of cancer progression, it appears that miR-200a 
functions as an oncomiR.  
 
miR-1 
 Predominantly thought to induce cardiac/skeletal muscle differentiation and 
development, miR-1 also increases during the development of prostate cancer (Figure 3-6) 
91. Similar to miR-200a, the level of miR-1 increases dramatically as the cells progress 
from an intermediate stage of tumor progression towards a more oncogenic phenotype. 
Results of the single miRNA assay agree with the overall trend obtained using the 
mIRCURY array based platform but the fold change observed differed. As seen for miR-
200a, analysis of miR-1 using a single assay revealed a much higher fold difference (7-
fold) than observed using the array.  
There are dozens of targets proven to be regulated by miR-1, the most well 
described is HDAC4 a histone deacetylase. Androgen insensitivity is commonly observed 
in most disseminated prostate carcinomas. Localization of HDAC4 in the nucleus of 
androgen insensitive cancer cell lines was observed and hypothesized to contribute to the 
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development of the hormone refractive phenotype 92. In the nucleus, HDAC4 represses 
genes that induce cellular differentiation. The mechanisms for sequestration of HDAC4 
in the nucleus of the androgen insensitive epithelial cells are not well understood. It is 
possible that accumulation of miR-1 in the cytoplasm by some yet undefined mechanism 
may play a role in the nuclear localization of HDAC4. Thus miR-1 may be an important 
oncomiR that drives prostate cancer progession.  
 
miR-375 
 Exhibiting a greater than 10-fold increase in the M12 subline, miR-375 has been 
shown by other groups to be of potential interest in the development of prostate cancer 93. 
miR-375 accumulates in the cytoplasm of tumor epithelial cells and increases in 82% of 
patient tumors. In our cell progression model, miR-375 exhibits an interesting behavior. 
Its expression decreases slightly in the early stages of tumorigenesis and increases as the 
cells move toward a more tumorigenic, metastatic phenotype (Figure 3-6). The overall 
observation of miR-375 behavior agrees in both the array and single assay experiments. 
However, the fold change measured in the array based format was higher than that 
determined using the single assay experiment reversing the trend seen earlier for miRs-
200a and -1. Interestingly, the detection of circulating miR-375 in blood has been 
suggested as a biomarker for CaP, which would agree with our data suggesting that miR-
375 functions as an oncomiR 94.  
 The X-box binding protein 1 (XBP1) is a basic region-leucine zipper transcription 
factor involved in the unfolded protein response system 95. Accumulation of unfolded 
proteins (ER stress) in the lumen of the endoplasmic reticulum (ER) leads to activation of 
  - 82 -
pathways that decrease protein expression, increase degradation and protein folding 96. 
As ER stress continues to develop, induction of pro-apoptotic pathways occurs. 
Inadequate responses to ER stress can cause a cell to proliferate uncontrollably. 
Downregulation of XBP1 inversely correlates with prostate cancer progression ie as 
XBP1 decreases the Gleason grade of the prostate tumor increases 95. miR-375 has been 
shown to target XBP1 causing translational inhibition of the protein leading to increased 
ER stress. Increased expression of miR-375 may lead to CaP progression.  
 
miR-34a 
 In our cell model, miR-34a functions as an oncomiR and is approximately 5-fold 
higher in M12 than in P69 cells (Figure 3-6). Although the miRNA screen and individual 
assays agree in trend, again there is disagreement in fold differences. The miRNA screen 
dramatically over estimated the difference of miR-34a between the P69 and M12 cells. 
Similar to miR-375, earlier stages of pathogenesis display decreased levels of miR-34a. 
As the cells move toward a more oncogenic state, the level of miR-34a increases.  
 Traditionally thought to be a tumor suppressor regulated by P53, there is evidence 
that miR-34a may be highly cell type/tumor type dependent 97, 98. Nearly 90% of prostate 
tumors show high levels of miR-34a using an in situ hybridization technique 98.  
Knockdown of miR-34a with an antagomir in HeLa cervical cancer and MCF breast 
cancer cells resulted in decreased proliferation. It is hypothesized that increased 
expression of miR-34a in tumors may result in an anaerobic metabolic capacity. It is well 
known that many solid tumors contain hypoxic regions due to structural and functional 
abnormalities in supporting blood vessels 99. Increases in the anaerobic potential of 
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tumors can sustain cell growth and proliferation in spite of the lack of oxygen due to 
increases in expression of miR-34a. Our analysis suggests that miR-34a acts as an 
oncomiR in our cell model.   
 
miR-146a 
 Human miR-146a displays opposing behaviors as the cells become more 
tumorigenic. In the early stages of oncogenesis (M2182), miR-146a expression increases 
approximately 2-fold (Figure 3-7). However; as the cells move to the more highly 
tumorigenic, metastatic phenotype, expression of miR-146a decreases dramatically (60-  
fold).  
 Interestingly, a literature search reveals that miR-146a displays contradictory 
behaviors dependent upon androgen sensitivity 100. In high grade, hormone refractory 
prostate cancer, there is a loss of miR-146a expression. There exists an inverse 
correlation between miR-146a expression and severity of CaP. Increased tumorigenicity 
is accomplished through the Rho-ROCK1 pathway 101. ROCK1 is a member of the Rho-
GTPase family, driving tumorigenesis by imparting an unlimited proliferative potential, 
ability to evade apoptosis, and establishment of distant metastastic lesions 102. Some 
evidence suggests that ROCK1 may contribute toward the EMT and aid in extravasation 
of cancer cells from their non-tumorigenic neighbors. Thus loss of miR-146a may induce 
an oncogenic transformation and miR-146a may be a potential biomarker for CaP 
progression.  
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Figure 3-7: Validation of tumor suppressors using single assay format 
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Figure 3-7: Validation of tumor suppressors using single assay format  
RNA (50 ng) was reverse transcribed into cDNA using a universal RT PCR system 
(Exiqon, Denmark). Each assay was conducted in triplicate with an LNA modified 
oligonucleotide primer. SYBR green was used as the fluorescent reporter and PCR 
reaction was performed in an ABI7300. Data are presented as the mean fold change 
between each cell type relative to P69.    
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miR-127-3p  
 In our model, the level of miR-127-3p drops dramatically during the early phases 
of cancer cell progression and is not found to be expressed in the M12 cells (Figure 3-7). 
Like many miRNAs, miR-127-3p resides in a polycistronic transcript in which all 
components are under the control of a common promoter. As mentioned, pri-mir-127 
gives rise to two fully functional mature miRNAs.  
 Literature shows that miR-127-3p is a component of the miR-433/miR-127 cluster 
on chromosome14 that is expressed in the normal, non-tumorigenic prostate gland 103, 104. 
Methylation of a specific CpG island in tumor cells silences expression of the mir-127 
precursor, while not affecting other members of the cluster. Treatment of the tumor cell 
with 5'-Aza-CdR results in activation of pri-mir-127 confirming a role for methylation in 
regulating miR-127-3p expression.  miR-127-3p expression correlates with a less 
tumorigenic, non-metastatic phenotype.  
 B-cell lymphoma 6 (BCL-6) is a known target of miR-127-3p (Table 3-2) 104. 
BCL-6 is a transcriptional repressor best known for its role in the development of 
lymphoma. However, its expression increases in several solid tumors including tumors of 
the prostate. A well known target of BCL-6 repression is the programmed cell death 2 
(PCD2) gene, that is involved in apoptosis 105. Induction of BCL-6 protects cells from 
apoptosis, allowing cells to proliferate in spite of the accumulation of genetic mutations. 
Decreased expression of miR-127-3p due to promoter methylation leads to accumulation 
of BCL-6 and subsequent repression of PCD2 allowing cells to escape apoptosis and 
proliferate uncontrollably. Thus miR-127-3p functions as a tumor suppressor.  
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miR-127-5p 
 As pri-mir-127 gives rise to two functional mature miRNAs, it is expected that 
silencing of the precursor would result in decreases of the level of both mature miRNAs. 
Our analysis confirms that both levels of miR-127-3p and miR-127-5p decrease as the 
cells gain tumorigenic properties.  
 
miR125-b  
   Human miR-125b was greatly decreased in the highly tumorigenic, metastatic 
M12 cell line (Figure 3-7). In early stages of tumorigenicity, miR-125b levels decrease 
and continue to decrease as oncogenesis proceeds. Overall from P69 to M12, there is 
approximately a 20-fold drop in the level of miR-125b. Again, this number does not 
agree with the fold change found using the miRCURY Human Panel where miR-125b is 
barely detectable in the M12 variant giving rise to a less accurate number. In spite of this 
discrepancy, both methods confirm a highly differential expression of miR-125b. There 
are many proven targets of miR-125b including the epidermal growth factor receptors 
ErbB2 and ErbB3 106.  Increased levels of ErbB2/ ErbB3 lead to uncontrolled cellular 
proliferation and inhibition of apoptosis through activation of the AKT pathway. Patients 
with metastatic, hormone-refractory CaP all showed an increase in EGFR expression 107. 
Overexpression of EGFR receptors has been shown to be associated with poor outcomes 
from CaP 108.  
 A recent study that compared matched prostate tumorigenic epithelium to benign 
epithelium revealed significant down regulation of miR-125b 109. Decreased expression 
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of miR-125b can be used as a potential biomarker for the discrimination of malignant 
from benign epithelium. Due to the evidence of involvement of the EGFR pathway in 
prostate cancer progression, miR-125b makes an attractive therapeutic target as well. 
Increasing expression of miR-125b in highly tumorigenic and metastatic prostate cancer 
cells may decrease tumorigenicity by inhibition of the EGFR family of growth factor 
receptors. In this cell progression model, miR-125b clearly functions as a tumor 
suppressor.  
 
Summary of cell line data  
Numerous changes occur during the transition from a poorly tumorigenic 
phenotype to a highly oncogenic state. There are many miRNAs dysregulated as a cell 
gains increased tumorigenic propensity. In this study, we identified approximately 200 
miRNAs with altered expression patterns that may contribute to the development of CaP 
using an array based format. A subset of these miRNAs was chosen based on their 
interaction with critical proteins and their expression was analyzed across a cancer 
progression model. Overall the expression patterns determined using the array based 
format were confirmed using the single miRNA assay, but in some cases the fold changes 
did not agree across the two methods. Nevertheless, literature searches confirmed that 
each miRNA may indeed contribute to cancer progression through the modulation of 
important cellular pathways. The possible interplay of these pathways in regulating CaP 
will be further explored below.    
 Interestingly, two of the chosen miRNAs regulated the PI3K/ AKT pathway. As 
discussed, loss of miR-125b leads to increased levels of ERBB2/ ERBB3 accelerating 
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cell proliferation and inhibition of apoptosis (Figure 3-8). Increased expression and 
accumulation of miR-22 leads to decreased levels of PTEN a known inhibitor of PI3K. 
Loss of PI3K repression leads to increased cell proliferation and avoidance of apoptosis.      
 Utilization of in vitro models of cancer progression and metastasis has occurred 
since the advent of the HeLa immortalized cell line. Since that time, hundreds of cell 
lines have been created that are used to study nearly every form of cancer. CaP has been 
traditionally studied using three major cell lines and their derivatives (Du145, LnCaP, 
PC3).  
 The cell lines used in this research are unique. The primary cell used in this study 
is derived from non-tumorigenic tissue, not from metastatic lesions. The highly 
tumorigenic, metastatic sublines were created using in vivo selection methods. As such, 
they are genetically related and offer an insight into the molecular perturbations that 
underlie tumorigenesis and metastasis. In vitro models of cancer progression offer many 
advantages; they are easy to handle, virtually limitless, essentially homogeneous, and are 
relatively inexpensive to study 110. 
 Potential limitations of in vitro research include; accumulation of genetic 
mutations as cells propagate in culture, contamination of cell lines by bacteria, inability 
to replicate in vivo structure, and elimination of environmental cues by separation of cells 
from their stroma. Although, there are limitations to in vitro assays, they still provide an 
opportunity to elucidate molecular alterations affecting cancer development. For these 
reasons, it is highly unlikely that a single model system can accurately reflect all aspects 
of disease progression and it is important to utilize a variety of methods to ensure that 
findings from cell lines replicate growth of tumor in man. Molecular changes observed in  
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Figure 3-8: Model of miRNA dysregulation of PI3K/ AKT pathway 
 
Figure 3-8: Model of miRNA Dysregulation of PI3K/ AKT Pathway  
Evaluation of miRNA expression changes using the Exiqon LNA™ miRCURY system 
revealed the loss of miR-125b with an increase in miR-22 as cells gain tumorigenic 
potential. The literature shows that mR-125b and miR-22 regulate the PI3K/ AKT 
pathway. Combined dysregulation of both miRNAs may affect oncogenesis through 
pathway modulation. Protein nodes in red are known inducers of tumor formation. The 
node in blue is a well described tumor suppressor, and yellow nodes are miRNAs that 
inhibit their protein targets.  
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 cell lines must be confirmed in human tissue and its role in prostate cancer defined. It is 
unclear if many of the observed expression differences are causal or simply as a result of 
tumorigenic behavior.  
 
Confirmation of miRNA dysregulation in human tumors 
 Transformation of benign prostate cells to disseminated metastatic lesions can 
best be understood in the context of the native environment of the prostate gland. 
Determining molecular changes contributing to pathogenesis in the prostate is 
complicated by the heterogeneity of the tissue. Relevant cell populations often only 
comprise a small percentage of whole tissue 111. Ideally, expression profiling will be 
carried out in pure cell populations as to minimize the confounding variables contributed 
by heterogeneous cell populations.  
 To confirm findings, miRNA dysregulation was assessed in tumors obtained after 
radical prostatectomy. In consultation with a board certified pathologist (Ema Dragoescu, 
MD), approximately 25 potential fresh, frozen samples were identified and examined for 
evidence of prostate cancer. Following prostatectomy, core samples are obtained from the 
removed prostate. An attempt is made to obtain a representative core sample containing 
regions of prostate tumor using external palpation. Many of the core samples evaluated 
did not meet inclusion criteria for this study. Either the amount of tumor was inadequate 
or there were not enough benign glands for matched comparison. Of the samples 
evaluated, four were found to be suitable for study inclusion as they contained both 
benign and tumorigenic epithelial glands. One of the four patients identified was 
eventually excluded from the study due to an inability to obtain adequate RNA to analyze 
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as core samples missed most of the tumor. Ideally, additional samples will be profiled in 
the future. However, one is limited to the number of prostatectomy procedures performed 
in their facility, patient consent, and adequate levels of tumor in the core samples.  
 Pure cell populations can only be obtained from a heterogeneous tissue with 
techniques such as laser capture microdissection 40, 112. LCM allows for direct 
visualization of the tissue and extraction of selected cells using UV or IR laser pulses. 
Selected cells are adhered to a polymer and are utilized for downstream analysis of 
biological macromolecules.  
 Although there have been numerous array based studies utilizing human prostate 
tissue, there is little agreement on specific miRNAs dysregulated during tumorigenesis 90. 
A potential reason for disagreement among studies may be contamination of tumor tissue 
with adjacent smooth muscle, stroma, blood vessel, lymphocytes, and benign epithelium. 
Whole prostate tissue stained with H&E is visualized microscopically and cells of interest 
are selected (Figure 3-9a). Often, core samples contain several tissue types. It is not 
uncommon to find regions of high grade adenocarcinoma located immediately adjacent to 
benign epithelial glands. Nearly pure populations of the selected cell type are captured 
onto the polymer cap and residual tissue is left behind (Figure 3-9b and 3-9d). LCM 
analysis is important as findings from whole tissue may be complicated by the presence 
of unrelated, contaminating tissue such as prostatic urethra (Figure 3-9c). Previous 
studies that evaluate miRNA expression using homogenized whole prostate tissue are 
likely to be contaminated with other tissue types. Cell specific /tumor specific profiles 
can be obscured when whole tissues are homogenized and extracts are used in 
downstream applications. LCM is necessary to minimize confounding variables and    
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Figure 3-9: Laser capture microdissection of human prostate tissue 
 
 
Figure 3-9: Laser capture microdissection of human prostate tissue 
Human prostate tissue obtained after prostatectomy was flash frozen in liquid nitrogen. 
Samples stained with hematoxylin and eosin (H&E) following dehydration with ethanol 
and xylene were mounted on uncharged glass slides. Representative tissue samples 
displaying the heterogeneity of prostate tissue are shown (A). Following microdissection, 
only regions of stroma remained. Epithelial tumor cells were extracted and retained for 
analysis (B).  LCM is required to minimize variation due to tissue heterogeneity. Regions 
of Prostatic urethra are visible in panel C and if included in a whole tissue sample could 
complicate analysis (C). Epithelial tumor cells are retained on LCM cap (D).   
A. B. 
C. D. 
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obtain expression profiles that are truly reflective of the tumorigenic components of the 
gland. Ideally, different grades of tumor tissue would be separated from one another and 
their expression profile quantified in isolation. Within the tumor component of tissue, it is 
normal to find glands of varying grades and stages. This approach assesses differential 
regulation of miRNA within each distinct phase of tumor progression. However; when 
using fresh frozen tissue, time is a limiting factor. 
  In order to obtain RNA that adequately represents the expression profile of the 
tissue, dissection must be completed within 30 minutes. Due to the time limitation, it is 
difficult to completely isolate tumor sub-types from one another. Thus in this study, 
whenever fresh frozen tissue was utilized, all tumor sub-types were grouped together. 
Future studies will further characterize miRNA dysregulation in tumor sub-types using 
formalin-fixed paraffin embedded (FFPE) prostate samples. Ideally, fresh frozen samples 
will be compared to their FFPE counterpart to minimize inter-patient variability. In this 
study, we have evaluated one FFPE patient sample to profile miR-125b behavior across 
epithelial sub-types. The expression of other selected miRs was analyzed in the three 
remaining frozen tissue samples (Figure 3-10 through Figure 3-12). 
 Evaluation of all proposed oncomiRs revealed that there is not one miRNA in our 
sub-group that universally increases as cancer progresses (Figure 3-10 – Figure 3-12). It 
is expected that there will be great variation in the expression profile of miRNAs 113 . 
Differences in genetic sequence, epigenetic regulation and acquisition of somatic 
mutations may lead to disease and differential miRNA dysregulation. Some miRNAs 
demonstrate common patterns of expression that suggest their regulation may be 
genetically inherited.  
  - 94 -
 
 
 
 
 
 
 
 
 
  
Figure 3-10: Evaluation of miRNA dysregulation in patient 09-362-V002 
RNA (50ng) was reverse transcribed into cDNA using a universal RT PCR system 
(Exiqon, Denmark). Each assay was conducted in triplicate with an LNA™ modified 
oligonucleotide primer set. SYBR green was used as the fluorescent reporter and the PCR 
reaction was performed in an ABI7300. Data are presented as the mean fold change 
between tumor cells relative to benign epithelium. OncomiRs predicted to be 
dysregulated during tumorigenesis are displayed in Panel A. Tumor suppressors are 
shown in Panel B.  
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Figure 3-10: Evaluation of miRNA dysregulation in patient 09-362-V002 
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Figure 3-11: Evaluation of miRNA dysregulation in patient 08-347-V007 
RNA (50ng) was reverse transcribed into cDNA using a universal RT PCR system 
(Exiqon, Denmark). Each assay was conducted in triplicate with an LNA™ modified 
oligonucleotide primer set. SYBR green was used as the fluorescent reporter and the PCR 
reaction was performed in an ABI7300. Data are presented as the mean fold change 
between tumor cells relative to benign epithelium. OncomiRs are displayed in panel A 
and tumor suppressors are shown in panel B.  
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Figure 3-11: Evaluation of miRNA dysregulation in patient 08-347-V007 
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Figure 3-12: Evaluation of miRNA dysregulation in patient 09-225-V002 
RNA (50ng) was reverse transcribed into cDNA using a universal RT PCR system 
(Exiqon, Denmark). Each assay was conducted in triplicate with an LNA™ modified 
oligonucleotide primer set. SYBR green was used as the fluorescent reporter and the PCR 
reaction was performed in an ABI7300. Data are presented as the mean fold change 
between tumor cells relative to benign epithelium. OncomiRs are displayed in panel A 
and tumor suppressors are shown in panel B.  
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Figure 3-12: Evaluation of miRNA dysregulation in patient 09-225-V002 
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 It has been shown that some miRNAs differ in their expression patterns between 
African-American and Caucasians demonstrating that different human populations vary 
in their global miRNA expression patterns. Due to the high degree of variance, it is 
essential that researchers profile a large number of patients to identify key miRNAs that 
may contribute to CaP progression. However, at this point we only had three samples to 
profile and some interesting circumstances are discussed below which could contribute to 
the lack of universal findings. 
Due to technical limitations in acquiring use of the LCM facility, one sample 
remained stored at -80° C after mounting onto slides for an extended period of time ie 6 
months (08-347-V007). Thus, RNA extracted from this patient may be of dubious quality 
and not accurately reflect all miRNA changes (Figure 3-11). Due to limited RNA 
availability not all miRNAs could be assessed.  
 Another patient (09-225-V002) presented with an interesting morphological 
condition. The glands of the prostate were atrophied. Although the attending pathologist 
described the condition as benign, the miRNA expression profile suggests otherwise. 
There is essentially no difference in oncomiR expression between the atrophied glands 
and the tumor epithelium (Figure 3-12).  It is possible that prostatic atrophy is not a 
benign lesion but may be an early form of cancer. Consistent with this hypothesis, 
literature shows that other authors have demonstrated that atrophied glands have 
increased production of proliferative markers, and decreased levels of apoptosis 114. 
Prostatic atrophy seems to be a pre-cursor to prostatic intraepithelial neoplasia and 
prostate carcinoma and is not the same as normal prostatic epithelium.  
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 One patient (09-362-V002) exhibited expected increased expression for all 
proposed oncomiRs with the exception of miR-200a (Figure 3-10). As discussed, there 
are opposing roles for miR-200a that are likely to be tumor type dependent and this 
discrepancy is justifiable. We put the most stock in this sample, as it was freshly prepared. 
Cells were captured and RNA was extracted within 4 days. Moreover, the tissue 
illustrated little abnormalities in cell type composition.  In addition, we obtained 
significant yields of high quality RNA from this individual as attested by analysis of 
sample composition on a bioanalyzer. However, these results need to be confirmed with 
additional human samples.  
 
Profiling of tumor suppressors in human tissue 
Contrary to our analysis of oncomiRs, all of the tumor suppressors identified in 
our cell progression model were confirmed in each patient sample analyzed (Figure 3-10 
– Figure 3-12). miR-127-3p and miR-127-5p both function as tumor suppressors; 
however, there remains some form of  differential regulation. Although differential 
expression was observed in the cell lines, human samples showed a reverse trend with 
higher levels of the 3p strand. miR-127-3p showed 3-4-fold higher expression levels 
when compared to miR-127-5p in human tumor samples.  
miR-125b showed significantly decreased expression (~5-fold) in all human 
samples analyzed thus far. Again this fold change is not as significant as estimated using 
the array based platform, but remains exciting nonetheless. As discussed, miR-125b is 
one of two miRNAs chosen that regulate the PI3K/AKT pathway leading to increased 
cell proliferation and apoptosis inhibition. Loss of miR-125b results in increased 
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expression of ERBB2/ERBB3, two members of the family of epidermal growth factor 
receptors. Anther study has shown widespread, but not universal downregulation of miR-
125b during the development of prostate cancer 115.  
This analysis indicates that it is easier to lose expression of a tumor suppressing 
miRNA rather than increase expression of oncomiRs. Loss of miRNA expression can be 
brought about by a number of events. Pre-cursor miRNAs are cleaved into their mature 
functional molecule by Drosha and Dicer processing. Differential expression of Drosha 
and Dicer could account for some of the loss of miRNAs in tumor tissue 116. Literature 
shows that Dicer levels are differentially regulated in various prostate tumors. 117
 Furthermore, over half of miRNA genes are located in regions of the genome that 
are sensitive to loss of heterozygosity (LOH). Epigenetic modifications have been shown 
to effect numerous miRNAs as well. Often hypermethylation of miRNA promoters 
inhibits expression of the pri-mirna thus decreasing the overall level of mature miRNA 
available.  
An ideal biomarker would be able to distinguish malignant cells from benign cells 
before histological changes occur as therapy is more likely to be successful. The loss of 
miR-125b in the tumor cells may be a potential indicator of cancer initiation and 
progression. In order to determine if miR-125b decreases in the early stages of cancer 
development, analysis of FFPE archived prostate samples was used to measure miR-125b 
in various types of prostate epithelium (Figure 3-13). Dissection of FFPE samples is not 
time limited and provides an ideal opportunity to more finely resolve changes that occur 
during tumor progression.  
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Interactions between cells and their microenvironment contribute to the 
maintenance of tissue homeostasis 118. Intricate intercellular signaling networks between 
the stroma and epithelium help to maintain normal tissue integrity. Communication 
failure within either the stromal cells or the epithelial cells may induce oncogenic 
transformation and contribute to cancer initiation or progression. Generation of a reactive 
stroma is generally thought to occur during early phases of tumor progression 119. 
Identification of miRNA changes driving the switch from normal to reactive stroma may 
result in a unique early indicator of prostate cancer. A slight increase in the level of miR-
125b is observed in the stroma of this sample compared to benign epithelial tissue (Figure 
3-13).  
Benign prostatic hyperplasia (BPH) is a common disorder that will affect nearly 
all men at some point in their life. BPH normally occurs in two distinct phases 120.  
During the first phase of disease progression, there is microscopic evidence that the 
glandular cells of the prostate increase in size. The second phase of BPH progression 
results in dysuria caused by macroscopic growth of the prostate gland resulting in partial 
obstruction of the prostatic urethra. It is generally thought that the presence of BPH does 
not increase a patient’s risk of developing CaP.  The level of miR-125b decreases in BPH 
cells when compared to normal benign epithelium (Figure 3-13). However, there is a 
great range of miR-125b levels in BPH cells as evident by the large standard deviation. It 
would be interesting to determine if BPH glands located closer to tumor cells display an 
altered miRNA expression portrait. 
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Figure 3-13: Evaluation of miR-125b expression in various epithelial subtypes  
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Figure 3-13: Evaluation of miR-125b expression in various epithelial subtypes  
A single FFPE prostate sample mounted in 10μm slices onto 20 slides was dissected with 
LCM into various epithelial subtypes and stroma. Using the PicoPure RNA extraction kit, 
total RNA was obtained and quantity estimated using an Agilent Bioanalyzer 2100 with 
the RNA Pico chip. RNA (20 ng) was converted into cDNA using the TaqMan® 
microRNA Reverse Transcription Kit (Life Technologies, Grand Island, NY). Q-PCR 
was performed with specific primers against miR-125b using the TaqMan® Universal 
Master Mix II with no Amp unerase (Life Technologies, Grand Island, NY). CT values 
were normalized using levels of the endogenous control (RNU48) and reported as fold 
differences using the ddCT method of Livak et al 74.  
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  Prostatic intraepithelial neoplasia (PIN) is considered to be a pre-cursor for the 
development of prostate carcinoma 121. PIN is characterized by increased proliferation of 
basal cells in the prostate gland without invasion into the underlying stroma. Many of the 
genetic changes that drive prostate cancer occur early in pathogenesis and are evident in 
PIN cells. Expression of the EGFR members ERBB2/ ERBB3 increase as the cells 
transition from a benign phenotype to PIN cells 122. As ERBB2/ ERBB3 are targeted by 
miR-125b, it is reasonable to suspect that miR-125b decreases as the cells transition. Our 
analysis confirms this hypothesis. miR-125b decreases 3- 4-fold when compared to the 
benign epithelium (Figure 3-13). This finding indicates the miR-125b may be useful to 
identify early pre-cancerous lesions and subsequent decreases in the level of miR-125b 
may help identify progressive tumor growth.  
In order for a tumor cell to set up a distant metastatic lesion, it must detach from 
its neighbors and invade the surrounding basement membrane. Numerous proteins have 
been implicated in the ability of a cell to acquire metastatic potential 123. Two proteins 
that affect the PI3K/ AKT pathway have been shown to impact the metastatic potential of 
a cell. Over-expression of ERBB2/ ERBB3 has been shown to increase a cell’s ability to 
become motile and invasive. Loss or reduction of PTEN has a similar phenotypic effect.  
Due to the combinatorial analysis implicating ERBB2/ ERBB3 as potential 
drivers of tumorigenesis negatively regulated by miR-125b whose level is reduced as 
tumorigenicity increases, it is reasonable to suspect that restoration of miR-125b would 
inhibit tumorigenic potential. Many studies have used miRNA overexpression as a means 
to identify function of the miRNA 124. Literature shows that the enforced expression of 
miR-125b impacts a cells ability to invade and migrate through the stroma of the prostate 
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tissue 125. Proof of this concept also exists in breast cancer where it was shown that 
increased expression of miR-125b in SKBR3 cells inhibits the ability of cells to migrate 
and invade through the down regulation of ERBB2/ERBB3 106. Down-regulation of miR-
125b is found in many solid tumors and promotes anchorage independent proliferation, 
cell migration and invasion. Loss of miR-125b seems to be an important step in the 
attainment of an oncogenic state.  
 
In Vitro metastasis assays  
Stable transformation of M12 cells with a pSIREN vector expressing the pre-mir-
125b sequence negatively affected the ability of M12 cells to migrate (Figure 3-14). After 
transfection and selection, restoration of expression was confirmed by qRT- PCR and the  
level of miR-125b was found to be 3-fold higher than the original M12 cells (Figure 3-
15). It is important to note that this fold of expression change is physiologically relevant. 
Most human tumors profiled in this study had a 3 - 5-fold drop in the level of miR-125b. 
Enforced overexpression of a miRNA past physiological levels may not reveal accurate 
results.  
Previous studies have demonstrated that restoration of a tumor suppressing 
miRNA (hsa-miR-17-3p) limits the ability of M12 cells to migrate in a Transwell assay 90. 
It is known that miR-17-3p downregulates the intermediate filament protein, vimentin, 
which is known to increase in highly tumorigenic, metastatic cells. M12 cells stably 
expressing mature miR-17-3p were used as a positive control to compare our miR-125b 
expressing cells. Like miR-17-3p, restoration of miR-125b expression inhibited cellular 
migration approximately 3- 4-fold. 
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Figure 3-14: Migration assay  
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Figure 3-14: Migration assay  
 
Cells (50,000) were plated in serum free media in the top chamber of a ThinCert™ tissue 
culture insert. Bottom chamber contained 500 μl of RPMI 1640, 5% FBS, supplemented 
with 10 ng/ml of EGF as a chemotractant agent. Cells were incubated for 20 hours and 
fixed with 0.025% glutaraldehyde for at least 20 minutes. Cells visualized by staining 
with 0.1% crystal violet in PBS for 30 minutes and the membrane was mounted on a 
glass slide. Cells were plated in triplicate across three wells and counted in 10 random 
fields. Total number of migratory cells was estimated by summing up each of the 
individual fields. The mean sum of the well is presented, along with the standard error.  
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 Figure 3-15: Restoration of miR-125b in M12 cells  
 
 
 
 
 
 
 
 
 
 
 
Figure 3-15: Restoration of miR-125b in M12 cells 
 
 M12 cells (500,000) were stably transformed with the human miR-125b sequence. Cells 
were transformed with purified plasmid (2.0 μg) using TransIT-LT1 (4.0 μl) transfection 
reagent (Mirus BioCorp, Madison, WI). Resistant cells were selected with 400 ng/ml 
Puramycin. Increased expression of miR-125b was verified by TaqMan™ qRT-PCR 
analysis. 
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 Secondary tumor sites are a culmination of a metastatic cascade of events in 
which the tumor cell becomes motile and invades the basement membrane 126. 
Restoration of miR-125b reduces the motility of cancer cells as evidenced by the 
Transwell assay shown in Figure 3-14. Invasion of a cell through the basement membrane 
is critical to the ability of a tumor to disseminate to other organs. The invasive potential 
of M12 cells with restored miR-125b was assessed using Transwell chambers coated with 
reduced growth factor basement membrane. Untreated M12 cells were highly invasive. 
M12 cells with restored miR-125b had a 75% lower invasive ability than M12 cells 
(Figure 3-16).  Again the results are quite similar to M12 cells with restored expression of 
miR-17-3p.  
 Together these assays suggest that restoration of miR-125b negatively impacts a 
tumor cell’s ability to metastasize. As most patients that die from prostate cancer, die 
from metastatic lesions, inhibition of metastasis may prolong the lives of patients 
suffering from prostate cancer. Targeted delivery of miR-125b to prostate cancer cells 
may offer a unique therapeutic alternative to limit morbidity and mortality associated 
with the disease. These analyses demonstrate that progressive loss of miR-125b increases 
the metastatic potential of tumor cells. 
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Figure 3-16: Invasion assay  
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Figure 3-16: Invasion assay  
Cells (50,000) were plated in serum free media in the top chamber of a ThinCert™ tissue 
culture insert. Bottom chamber contained 500μl of RPMI 1640, 5% FBS, supplemented 
with 10ng/ml of EGF as a chemotractant agent. Membrane was coated with Culturex® 
growth factor reduced basement membrane (60μl). Cells were incubated for 20 hours and 
fixed with 0.025% glutaraldehyde for at least 20 minutes. Cells visualized by staining 
with 0.1% crystal violet in PBS for 30 minutes and the membrane was mounted on a 
glass slide. Cells were plated in triplicate across three wells and counted in 10 random 
fields. Total number of migratory cells was estimated by summing up each of the 
individual fields. The mean sum of the well is presented, along with the standard error.  
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Chapter 4 
 
Reverse phase microArray identifies key proteins regulating cell growth  
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Reason for proteomics 
 Proteins have long been considered the workhorse of biological molecules. They 
are involved in nearly every cellular process from regulation of cell growth to initiation 
of apoptosis. Aberrant protein signaling pathways influence many processes that aid in 
tumorigenesis 37. Traditionally, gene array profiling has been used to distinguish genes 
that are dysregulated during the development of disease. It was traditionally thought that 
mRNA expression reflected actual protein levels. Knowledge of post-transcriptional 
control affecting mRNA translation challenges this traditional theory. It is now known 
that most genes are influenced by at least one miRNA. Thus, mRNA expression 
correlates poorly with protein levels.  
A more useful comparison would be miRNAs to protein levels, since protein 
synthesis is the direct target for miRNA regulation. It is true that some miRNA targeting 
results in mRNA degradation, but the more common outcome is a halt of translation. 
Although both methods of attack results in decreased protein levels, differences in 
mRNA expression correlate poorly with protein levels.  Actually, few mRNAs have been 
shown to be degraded by miRNA binding.  Obviously, direct measurement of protein 
content via a proteomic approach would be a better indicator of overall miRNA 
regulation than gene arrays. Unfortunately, gene arrays have been inappropriately used 
for this purpose, as they are freely available, relatively inexpensive and easily applied 
even by a novice. Proteomic arrays, on the other hand, require considerable expertise, a 
bevy of well characterized optimized antibodies and are not easily duplicated by the 
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novice. However, in order to identify proteins contributing to the development of CaP, 
one must utilize a high throughput proteomic method 
Identifying key proteins that are dysregulated during tumorigenesis may reveal 
common pathways that are altered during cancer progression. Cellular fate is determined 
by minute fluctuations in the proteome of the cell 37. The reverse phase protein 
microarray (RPMA) immobilizes hundreds of cellular lysates onto a nitrocellulose glass 
slide in a miniature dilution curve 112. The slide is probed with an antibody to the protein 
of interest and the level of the protein is accurately determined. This method requires one 
slide for each antibody of interest. In this capacity, we have been assisted by Drs. Lance 
Liottta and Emmanuel Petricoin III from George Mason University, leaders of this 
technology. Ultimately, the method is high throughput allowing a researcher to quantify 
hundreds of proteins across hundreds of samples.  
Materials and Methods  
Cell culture  
 Cells are cultured at 37° C in RPMI1640 with L-glutamine obtained from Gibco 
supplemented with 5% fetal bovine serum, 5 μg/ml insulin, 5 μg/ml transferrin, and 5 
μg/ml of selenium (ITS from Collaborative Research Bedford, MA). Inhibition of 
bacterial contamination was accomplished with the addition of Gentamycin (0.05 mg/ml). 
M12 cells stably transformed with the p-SIREN (M12+miR-17-3p and M12+miR-125b) 
vector were maintained with Puromycin (100 ng/ml). F6 cells were maintained with 
Geneticin (200 μg/ml) 24. All tissue culture cells were grown in T75 flasks and split when 
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confluent. Cells were pelleted after trypsin (0.25% in EDTA) digestion by centrifugation 
at 5000 RPM for five minutes. After washing, cell pellets were flash frozen in liquid 
nitrogen after washing and stored for at least 24 hours. Three representative cell pellets 
were harvested during three serial passages for a total of 9 samples analyzed for each 
sample type was sent to the George Mason University Center for Applied Proteomics and 
Molecular Medicine. Overall, a total of 12 cell types were sent for RPMA analysis. All 
cell types were variants of the progression model described and many were designed to 
overexpress miRNAs of interest.  
Reverse phase microarray  
 RPMA experiments were conducted at the George Mason University Center for 
Applied Proteomics and Molecular Medicine under the supervision of Dr Emmanuel 
Petricoin III. It is important to note that the cell pellets used for RNA extraction for 
miRNA profiling were also used for proteomics analysis. This approach minimizes 
variation from culture to culture. Briefly, cell pellets were lysed in a tissue extraction 
buffer and spotted on the nitrocellulose coated glass slide. Each lysate was spotted in a 
miniature dilution curve (1:1, 1:2, 1:4, 1:8, and 1:16) to ensure accurate quantification of 
each protein measured. Overall, the cellular lysate was spotted onto 111 slides and each 
incubated with a unique antibody. Data were returned to our group on a Microsoft Excel 
spreadsheet containing each cell type analyzed with each antibody of interest.  
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Statistical analysis  
 Using Microsoft Excel, a two sample equal variance T-test was used to test for 
significant differences among the P69 cells and M12 cells. The significance value was set 
at α = 0.05.  
Results  
Significantly different proteins  
 Although there were a total of 12 cell types sent for RPMA evaluation, this study 
focuses on the P69 and M12 variants. It was found that there were 17 significantly 
dysregulated proteins between P69 and M12 cells (Table 4-1). Comparing the set of 
dysregulated proteins to our subset of miRNAs dyesregulated during tumorigenesis 
revealed several proteins regulated in part by miR-125b. Due to our proven interest in 
miR125b, we have concentrated on these targeted proteins first.  Loss of miR-125b 
causes an increase during the transformation to a more tumorigenic phenotype of ErbB2 
(2-fold) / ErbB3 (2.1-fold) and PI3K (1.5-fold) (Figure 4-1). As mentioned previously, 
activation of the PI3K/ AKT pathway increases cellular proliferation, invasion and 
metastasis. Activation of the PI3K/ AKT pathway plays a central role in the development 
of an oncogenic phenotype 127. AKT activation is an essential survival mechanism in 
many cell types and is found in numerous forms of cancer including CaP.  
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Table 4-1: Statistically significant proteomics changes determined using RPMA 
Protein Fold change 
Receptor Tyrosine Kinase  
ErbB2 1.8 
ErbB3 2 
p-ErbB3 1.3 
p-PI3K 1.4 
p-BAD 1.7 
p c-KIT 700 
Cell Cycle   
p27 0.7 
Cyclin B1 0.6 
Apoptosis   
p-BCL2 1.2 
Cytochrome C 0.4 
Caspase 7 1.5 
Others  
Androgen Receptor 1.7 
p-c-KIT  700 
CD44 0.2 
p-GSK3A/B 1.2 
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Figure 4-1: Model of AKT activation in prostate cancer  
 
Figure 4-1: Model of AKT activation in prostate cancer 
Combinatorial analysis of miRNA expression profiling and reverse phase proteomics 
reveals activation of the PI3K/ AKT pathway. Inhibition of miR-125b leads to increased 
expression of ERBB2/ ERBB3, thereby accelerating proliferation and inhibiting 
apoptosis. Nodes in red have been shown to be lost during prostate cancer development. 
Nodes in green increases as the tumor became more oncogenic. Nodes in yellow were not 
either not statistically significant or were not able to be assessed in the current study as 
antibodies were not included.  
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 Literature shows that dysregulated PI3K activity is a major contributor to 
oncogenic transformation 128. Increased activity of PI3K increases phosphorylation of 
AKT and affects a number of downstream targets that impart oncogenic potential. 
Proteomics analysis shows that increased expression of both ErbB2 and ErbB3 lead to a 
statistically significant increase in the phosphorylation of PI3K (p-value = 0.002) (Figure 
4-2). AKT is activated by phosphorylation of two potential residues, serine-473 and 
threonine-308. Although not statistically significant, our results show a trend toward 
increased phosphorylation of serine-473. It is possible that with an increased sample 
number, we may be able to further resolve differences between samples and statistically 
show an increase in AKT activation. 
 AKT activation causes phosphorylation of BAD, a BCL-2 family member that 
induces apoptosis. Apoptosis results from the interaction of BAD and the BCL-Xl protein. 
In absence of phosphorylation, BAD induces cell death by phosphorylation of either 
serine-112 or serine-136 129. Phospho-BAD binds to 14-3-3 protein which sequesters 
BAD and inhibits apoptosis. Our analysis shows an increase in the phosphorylation of 
BAD, but not an increase in the basal expression of BAD. Taken together this data 
demonstrates that ErbB2/ ErbB3 accumulation activates the PI3K/ AKT pathway and 
inhibits apoptosis through phosphorylation of BAD.  
 RAS protein is a membrane bound protein that exists in 2 states of activation 130. 
When a GDP molecule is bound to the cytoplasmic side of the protein, RAS is inactive. 
GTP binding activates the RAS molecule and initiates a  
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Figure 4-2: Pathways increased during prostate tumorigenesis  
Analysis of RPMA data revealed that common members of the PI3K/ AKT pathway are 
activated during conversion of P69 cells to the more tumorigenic M12 variant. 
Overexpression of ErBB2/ ErbB3 and p-MET can also lead to activation of the RAS 
oncogenic pathway. Protein nodes in green were shown to be significantly upregulated 
during tumorigenesis (p-value <0.05). Proteins in yellow were not statistically significant. 
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Figure 4-2: Pathways increased during prostate tumorigenesis 
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series of events inside of the cell that ultimately results in cell proliferation, cellular 
differentiation, cell survival, and an increase in cell motility.  
 ErbB2/ ErbB3 phosphorylation recruits the growth-factor-receptor-bound-protein 
2 (GRB2) bound to SOS to the plasma membrane 130. SOS recruitment to the membrane 
brings it in close proximity to the RAS molecule. Due to their proximity, a nucleotide 
exchange occurs between the two proteins activating RAS. RAS activation sets off a 
cascade of events, ultimately ending in phosphorylation of ERK. The phosphorylation of 
MEK1 is an intermediate step in the activation of ERK. ERK can affect numerous targets 
in the nucleus. Transcription factors regulated by p-ERK affect proliferation, 
differentiation, cell survival and motility.  
 Our data show that downstream targets of RAS such as p-MEK and p-ERK are 
more active in the highly tumorigenic, metastatic M12 variant. There is approximately 5-
fold more p-ERK present in the M12 variant than there is in the P69 parental cell (p-
value=0.03). Over expression and activation of the EGFR receptors (ErbB2/ErbB3) 
activate two downstream pathways that independently affect proliferation, apoptosis, and 
mobility. Targeted therapies against only one pathway are likely to be ineffective. 
However, re-expression of miR-125b may be a viable alternative that can inhibit both the 
PI3K/AKT and the MAPK/ ERK pathways through repression of ErbB2 and ErbB3.  
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Chapter 5 
Summary and discussion  
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 Prostate cancer is a leading cause of death of men in the United States; it is 
estimated that 1 in 6 men will be affected by prostate carcinoma at some point in their life. 
Cancer development is a multifactorial process influenced by age, ethnicity, and sexual 
factors. These factors influence a person’s risk of developing prostate cancer. 
Traditionally, CaP was diagnosed with a digital rectal exam followed by transrectal 
biopsy of the gland. The advent of the PSA biomarker increased the likelihood of a man’s 
compliance with active screening methods. However, as it has become clear that the PSA 
test is not a reliable indicator of prostate cancer formation, there has become a need to 
develop more accurate biomarkers. Diagnostic rates have declined in the last few years, 
particularly in the African-American population and in persons without a college 
education. It is known that African-Americans have a much higher death rate from 
prostate cancer than their Caucasian counterparts. Biomarkers that are non-invasive and 
can indicate early tumor formation are critically needed to minimize death and suffering 
from this disease. 
 In recent years, miRNAs have gained attention as important mediators of 
numerous cellular processes. Differential regulation has been observed in the 
development of numerous pathologies including cancer. This study has shown that 
miRNAs tend to regulate highly connected proteins and transcription factors affecting 
numerous downstream cellular pathways when dysregulated. Additionally, we have 
demonstrated that highly connected proteins are more likely to be regulated by more than 
one miRNA. Thus, dysregulation of even a single miRNA may impact intracellular 
stability and induce oncogenic transformation.  
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MiRNA dysregulation is a wide spread problem occurring during the 
development of prostate cancer. Using a unique genetically related prostate cancer cell 
progression model, we identified approximately 200 miRNAs that potentially influence 
cancer initiation, progression and metastasis. Initial profiling was accomplished with the 
Exiqon miRCURY LNA™ based array platform. As miRNAs influence post-
transcriptional regulation of proteins, we identified key highly connected proteins using 
an innovative networks approach. Dysregulated miRNAs were ranked according to the 
sum connectivity of their proven targets. A subset of miRNAs was chosen for evaluation 
across all variants of the cancer progression model (5 oncomiRs, 3 tumor suppressors). 
Although all were identified to be dysregulated using the miRCURY array, several did 
not agree in estimated fold changes to single miRNA analyses. We conclude that array 
based platforms are ideal to determine gross regulation differences but true fold changes 
are only detectable with a single assay format.  
 miRNA changes were assessed using pure cell populations obtained after 
microdissection of human prostate tumor samples. Interestingly, only the identified tumor 
suppressors were universally confirmed in all of the human samples included in the study. 
One patient sample showed that many of the proposed oncomiRs increased during 
tumorigenesis but not all. This finding suggests that increased expression of oncomiRs 
may be tumor type dependent but loss of tumor suppressors is more universal. There are 
many mechanisms in which a tumor suppressor may be lost including epigenetic 
modification.  
 Our unique combinatorial approach integrated a bioinformatically driven 
networks method with high throughput miRNA screening and reverse phase proteomics 
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to identify key miRNAs and pathways associated with prostate cancer progression. This 
approach indicated that miR-125b may be an essential miRNA that drives prostate cancer 
progression as it is lost during the conversion of benign cells toward a more oncogenic 
state. At this point, our analysis focused in on miR-125b because of its regulation of the 
PI3K/ AKT pathway and its known involvement in cancer progression and initiation of 
metastasis. However, much of the knowledge regarding miR-125b dysregulation was 
discovered in breast cancer. Previous researchers have demonstrated that miR125b 
inhibits translation of the ERBB2/ ERBB3 members of the epidermal growth factor 
receptor family 106. Analysis of miR-125b expression across epithelial subtypes showed 
that its level began decreasing in early pre-cancerous lesions (PIN) and the level 
continued to decline as the cancer progressed. . 
 Support of a potential role of miR-125b affecting the PI3K/ AKT pathway was 
found using a reverse phase proteomics array in which we observed an increase in 
ERBB2/ ERBB3 and PI3K. The loss of miR-125b results in an increase in the level of 
ERBB2/ERBB3 and increased activation of PI3K. Stable restoration of miR-125b in M12 
cells decreased metastatic capability as evidenced by decreased cell migration and 
invasion through a basement membrane.  
 Various human tumors demonstrate progressive loss of miR-125b, suggesting that 
miR-125b may be a common tumor suppressor in numerous types of cancers 131. 
However, there have been conflicting findings with some studies showing an increase in 
the level of miR-125b, while others have shown that miR-125b decreases in prostate 
cancer development. As discussed previously, miR-125b is dependent upon androgen 
sensitivity during the development of CaP.  
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 There has been a large amount of effort in determining the role of miR-125b and 
ErbB2/ ErbB3 in breast cancer. Numerous reports have shown that loss of miR-125b in 
breast cancer decreases chances of survival and increases the likelihood of metastasis 131. 
Two potential CpG rich islands were located within 2000 bp upstream of miR-125b. One 
of the potential CpG islands was shown to be heavily methylated in highly tumorigenic 
cell lines and invasive breast cancer tissue. Treatment with 5-AZA-Cr restored expression 
of miR-125b. Taken together these data demonstrate that hypermethylation of the 
promoter of miR-125b decreases its expression in breast cancer.  
 Although there is ample evidence that loss of miR-125b occurs frequently in the 
development of breast cancer and its loss directly affects the levels of ErbB2/ErbB3. 
There is little evidence in prostate cancer for a role of miR-125b. Our study clearly 
demonstrates that in androgen independent sublines, miR-125b functions as a tumor 
suppressor. Similar to the study conducted by Ozen et al, our study found that miR-125b 
decreased in all prostate cancer tumors analyzed 115. Findings of this study confirm that 
miR-125b functions as a suppressor of tumor formation in the prostate gland and 
increases coordinately the levels of ErbB2/ErbB3 activating the PI3K/AKT and RAS 
oncogenes pathways. Taken together, these data suggest that loss of miR-125b may be an 
ideal biomarker for the identification of prostate cancer and potentially be used as a 
therapy to inhibit metastatic potential.  
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